

AD _____

Award Number: DAMD17-00-2-0002

TITLE: Support for the Resident Research Associateship Program with the U.S. Army Medical Research and Materiel Command

PRINCIPAL INVESTIGATOR: Judith K. Nyquist, Ph.D.

CONTRACTING ORGANIZATION: National Research Council
Washington, DC 2001-2736

REPORT DATE: March 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-03-2007		2. REPORT TYPE Annual		3. DATES COVERED 24 Jan 2006 – 23 Feb 2007	
4. TITLE AND SUBTITLE Support for the Resident Research Associateship Program with the U.S. Army Medical Research and Materiel Command				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-00-2-0002	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Judith K. Nyquist, Ph.D.				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Research Council Washington, DC 2001-2736				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT For Abstract see report					
15. SUBJECT TERMS Infectious disease; combat casualty care; chemical and biological Medical defense; military operational medicine; biomedical research					
16. SECURITY CLASSIFICATION OF:			UU	18. NUMBER OF PAGES 71	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Final Reports.....	23

THE NATIONAL ACADEMIES
Advisers to the Nation on Science, Engineering, and Medicine

National Research Council
RESEARCH ASSOCIATESHIP PROGRAM

with the

U.S. Army Medical Research and Materiel Command (AMRMC)

Annual Contract Technical Report

Report Period: 01/24/06 – 01/23/07

DAMD-17-00-2-0002

Publicity

The National Academies Research Associateship Programs for the report period were announced to the scientific community in the fall of the preceding year. Publicity materials describing the National Research Council- U.S. Army Medical Research and Materiel Command [AMRMC]. Programs were distributed in November to presidents, graduate deans, and heads of appropriate science and engineering departments and minority-affairs offices of all academic degree-granting institutions in the United States. An e-mail announcement of the programs was sent to these same contact points prior to each review deadline. Promotional materials were sent to Laboratory Program Representatives, Associateship Advisers, and other interested persons. General advertisements of programs were placed in leading scientific and engineering publications. Publicity materials and other related information were made available on the internet. Research Associateship Programs staff attended numerous professional scientific and engineering meetings and minority recruitment events to promote the various programs and to meet with prospective applicants throughout the year.

Requests

Application materials were distributed in response to specific requests for information about the AMRMC Research Associateship Program or as a result of general requests by persons whose fields of specialization appeared to be appropriate for the research opportunities available in the AMRMC laboratories.

Competition

Panel reviews of applicants for the Research Associateship Programs, including those with the Army Medical Research and Materiel Command are conducted in March, June, September, and/or January of each year. The following is a breakdown of the action taken with the applications during the report period.

	Sept review of Aug app-06	Mar review of Feb app-06	June review of May app-06	Nov review of Jan app-07	TOTAL
TOTAL APPLICATIONS	3	11	5	8	27
Number of Applications Reviewed	3	11	5	8	27
Applications not recommended (did not pass Review)	0	0	0	1	1
Applications Recommended (passed Review)	3	11	5	7	26
Awards offered	3	9	3	4	19
Awards accepted	3	9	3	4	19
Awards declined	0	0	0	0	0
Awards withdrawn by RAP (NRC officially withdrew award <i>after</i> it had been accepted.)	0	1	0	0	1

Associates' Citizenship

Associates on tenure between 08/01/05 - 07/31/06 were citizens of the following countries:

37	U.S. citizens		
6	U.S. permanent residents		
1	India (Pending Perm. Residency)	1	Russia(J-1 Research Scholar)
2	Australia(J-1 Research Scholar)	1	Thailand(J-1 Research Scholar)
1	Brazil(J-1 Research Scholar)		
1	France(J-1 Research Scholar)		
1	Germany(J-1 Research Scholar)		
1	Ghana(J-1 Research Scholar)		
1	Ireland(J-1 Research Scholar)		
1	Japan(J-1 Research Scholar)		
1	New Zealand(J-1 Research Scholar)		
1	People's Republic of China(F-1 OPT)		

U.S. Army Medical Research and Materiel Command

4/30/2007 Page 1 of 3

Associate Name+ Adviser	Center	Tenure Dates Start/End	Termination Report	Adviser Report
Andres, Devon Katherine <i>Dr. Radharaman Ray</i>	U.S. Army Medical Research Institute of Chemical Defense	5/3/2006 - 5/2/2007		
Beitzel, Brett Forrest <i>Dr. Connie S. Schmaljohn</i>	U.S. Army Medical Research Institute of Infectious Diseases	1/12/2004 - 1/11/2008		
Bhonsle, Jayendra Bhausahab <i>Dr. Donald P. Huddler</i>	(S) Walter Reed Army Institute of Research	7/6/2004 - 1/5/2008		
Bradfute, Steven Blake <i>Dr. Thomas W. Geisbert</i>	U.S. Army Medical Research Institute of Infectious Diseases	2/16/2005 - 2/15/2008		
Brittingham, Katherine Tracey Cecil <i>Dr. Sina Bavari</i>	U.S. Army Medical Research Institute of Infectious Diseases	9/11/2003 - 9/10/2007		
Cashman, Kathleen Anne <i>Dr. Mary C. Guttieri</i>	U.S. Army Medical Research Institute of Infectious Diseases	7/11/2005 - 7/10/2007		
Curtis, Kristopher Michael <i>Dr. Michael D. Parker</i>	U.S. Army Medical Research Institute of Infectious Diseases	8/15/2003 - 10/6/2006	Received	Not Recd
Dupuy, Lesley Conrad, Jr <i>Dr. Connie S. Schmaljohn</i>	U.S. Army Medical Research Institute of Infectious Diseases	5/2/2003 - 7/1/2006	Received	Not Recd
Emerson, Ginny Leigh <i>Dr. Robert G. Ulrich</i>	U.S. Army Medical Research Institute of Infectious Diseases	3/1/2004 - 4/14/2006	Received	Not Recd
Enterlein, Sven Gunter <i>Dr. Sina Bavari</i>	U.S. Army Medical Research Institute of Infectious Diseases	12/18/2006 - 12/17/2007		
Filippov, Andrei Alexandrovich <i>Dr. Apurba K. Bhattacharjee</i>	(S) Walter Reed Army Institute of Research	7/18/2005 - 7/17/2007		
Foley, Desmond Hector <i>Dr. Richard C. Wilkerson</i>	(S) Walter Reed Army Institute of Research	2/17/2004 - 9/16/2006	Received	Received
Fritz, Elizabeth Ann <i>Dr. Lisa E. Hensley</i>	U.S. Army Medical Research Institute of Infectious Diseases	3/3/2003 - 9/2/2006	Received	Received
Furtado, Marcio de Araujo <i>Dr. Debra L. Yourick</i>	Walter Reed Army Institute of Research	9/25/2006 - 9/24/2007		
Ghosh, Kashinath <i>Dr. Edgar D. Rowton</i>	(S) Walter Reed Army Institute of Research	8/1/2005 - 10/31/2007		
Glynn, Audrey Rose <i>Dr. Douglas S. Reed</i>	U.S. Army Medical Research Institute of Infectious Diseases	11/6/2006 - 11/5/2007		
Goff, Arthur James <i>Dr. Lisa E. Hensley</i>	U.S. Army Medical Research Institute of Infectious Diseases	8/20/2004 - 10/31/2006	Received	Received
Golden, Joseph Walter <i>Dr. Jay W. Hooper</i>	U.S. Army Medical Research Institute of Infectious Diseases	4/4/2005 - 4/3/2008		
Hoard-Fruchey, Heidi Marie <i>Dr. Michael Adler</i>	U.S. Army Medical Research Institute of Chemical Defense	7/19/2004 - 4/28/2006	Received	Not Recd
Honko, Anna Nichole <i>Dr. Lisa E. Hensley</i>	U.S. Army Medical Research Institute of Infectious Diseases	6/1/2006 - 5/31/2008		
Jensen, Victoria Margaret <i>Dr. Lisa E. Hensley</i>	U.S. Army Medical Research Institute of Infectious Diseases	7/19/2004 - 3/31/2007		
Jirage, Dayadevi Balappa <i>Dr. Norman C. Waters</i>	(S) Walter Reed Army Institute of Research	8/22/2005 - 10/10/2007		

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

U.S. Army Medical Research and Materiel Command

4/30/2007 Page 2 of 3

Associate Name+ Adviser	Center	Tenure Dates Start/End	Termination Report	Adviser Report
Johnson, Erik Andrew <i>Dr. Robert K. Kan</i>	U.S. Army Medical Research Institute of Chemical Defense	1/3/2005 - 1/2/2007	Received	Not Recd
Jones, Juli Erin <i>Dr. Allen Cymerman</i>	U.S. Army Research Institute of Environmental Medicine	2/6/2006 - 2/5/2008		
Kaba, Stephen Abanega <i>Dr. David E. Lanar</i>	Walter Reed Army Institute of Research	8/1/2005 - 4/30/2008		
Kalina, Warren Vincent <i>Dr. Sina Bavari</i>	U.S. Army Medical Research Institute of Infectious Diseases	9/10/2004 - 9/9/2007		
Keener, William Kelvin <i>Dr. Mark A. Poli</i>	(S) U.S. Army Medical Research Institute of Infectious Diseases	10/1/2004 - 9/30/2007		
Keyser, Brian Michael <i>Dr. Radharaman Ray</i>	U.S. Army Medical Research Institute of Chemical Defense	5/4/2006 - 5/3/2007		
Klas, Sheri Denet <i>Dr. Robert G. Ulrich</i>	U.S. Army Medical Research Institute of Infectious Diseases	12/6/2004 - 2/28/2006	Received	Not Recd
Kremenevskiy, Igor <i>Dr. Anthony E. Pusateri</i>	U.S. Army Institute of Surgical Research	9/6/2005 - 9/1/2006	Received	Received
Langston, Jeffrey Lamar <i>Dr. Gary A. Rockwood</i>	U.S. Army Medical Research Institute of Chemical Defense	5/12/2003 - 5/11/2006	Received	Not Recd
Liepinsh, Dmitry <i>Dr. Urszula Krzych</i>	Walter Reed Army Institute of Research	4/18/2006 - 4/17/2008		
Ling, Yun <i>Dr. Ashima Saxena</i>	Walter Reed Army Institute of Research	12/4/2006 - 12/3/2007		
McGann, Patrick Timothy <i>Dr. Apurba K. Bhattacharjee</i>	Walter Reed Army Institute of Research	1/8/2007 - 1/7/2008		
Miroshnikova, Olga Vyatcheslavovna <i>Dr. Ai J. Lin</i>	Walter Reed Army Institute of Research	2/25/2003 - 2/24/2006	Received	Received
Morefield, Garry Lee <i>Dr. Robert G. Ulrich</i>	U.S. Army Medical Research Institute of Infectious Diseases	5/12/2004 - 2/9/2007		
Nicoll, William Stanley <i>Dr. David E. Lanar</i>	Walter Reed Army Institute of Research	4/1/2005 - 3/31/2007		
Noble, Schroeder Marie <i>Dr. Donald P. Huddler</i>	Walter Reed Army Institute of Research	10/4/2005 - 10/3/2007		
O'Brien, David Kenneth <i>Dr. Arthur M. Friedlander</i>	U.S. Army Medical Research Institute of Infectious Diseases	7/1/2003 - 11/30/2006	Not Recd	Not Recd
Pearson, Brooke <i>Dr. Arthur M. Friedlander</i>	U.S. Army Medical Research Institute of Infectious Diseases	7/14/2003 - 10/13/2006	Received	Received
Picchioni, Dante <i>Dr. Thomas J. Balkin</i>	Walter Reed Army Institute of Research	7/5/2005 - 7/4/2007		
Reeves, Tony Elvern <i>Dr. David E. Lenz</i>	U.S. Army Medical Research Institute of Chemical Defense	6/1/2006 - 5/31/2007		
Rickards, Caroline Alice <i>Dr. Victor A. Convertino</i>	U.S. Army Institute of Surgical Research	5/31/2005 - 5/30/2008		
Ruff, Albert Leonard <i>Dr. James F. Dillman, III</i>	(S) U.S. Army Medical Research Institute of Chemical Defense	6/28/2006 - 6/27/2008		

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

U.S. Army Medical Research and Materiel Command

4/30/2007 Page 3 of 3

Associate Name+ Adviser	Center	Tenure Dates Start/End	Termination Report	Adviser Report
Rupp, Tracy Lynn <i>Dr. Thomas J. Balkin</i>	Walter Reed Army Institute of Research	1/23/2006 - 1/22/2008		
Shiraki, Hiroaki <i>Dr. Ai J. Lin</i>	(S) Walter Reed Army Institute of Research	11/13/2006 - 11/12/2007		
Silvestri, Lynn Shields <i>Dr. Sina Bavari</i>	U.S. Army Medical Research Institute of Infectious Diseases	9/7/2004 - 1/31/2006	Received	Not Recd
Swanson, Katherine Irene <i>Dr. Russell E. Coleman</i>	Walter Reed Army Institute of Research	11/21/2005 - 11/20/2007		
Takhampunya, Ratree <i>Dr. Huo-Shu H. Huong</i>	Walter Reed Army Institute of Research	12/4/2006 - 12/3/2007		
Taylor, Shannon Lynn <i>Dr. Connie S. Schmaljohn</i>	U.S. Army Medical Research Institute of Infectious Diseases	6/8/2005 - 6/7/2007		
Tonduli, Laura Sabina <i>Dr. Bhupendra P. Doctor</i>	Walter Reed Army Institute of Research	2/17/2004 - 12/15/2006	Received	Not Recd
Toth, Stephen I. <i>Dr. Syed A. Ahmed</i>	(S) U.S. Army Medical Research Institute of Infectious Diseases	3/13/2006 - 3/12/2008		
Urso, Maria Laina <i>Dr. Edward J. Zambraski</i>	U.S. Army Research Institute of Environmental Medicine	7/10/2006 - 9/21/2006	Received	Received
Weeks, Christine Marie <i>Dr. George C. Tsokos</i>	Walter Reed Army Institute of Research	3/1/2006 - 8/31/2007		
Wilson, Paul Anthony <i>Dr. Jaques Reifman</i>	Center for Biomedical Computations Research	12/1/2005 - 3/30/2007		
Yokota, Miyo <i>Dr. Larry G. Berglund</i>	(S) U.S. Army Research Institute of Environmental Medicine	3/29/2006 - 3/28/2008		

56 Associates Listed

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

Recommended Candidates 1/24/2006 - 1/23/2007
U.S. Army Medical Research and
Materiel Command

Attachment 2

4/30/2007 Page 1 of 5

February 2006

1- Recommended

TANG, SHUANG
Citizenship: People's Republic of China
Adviser: Dr. Sina Bavari
Research Field: 3298
Research Title: Development of a Cell-Free System Utilizing Established Minigenome Replicons for the Study of Filovirus Transcription and Replication

Ph.D. Date: 2000
Shanghai Inst of Biochemistry

A- Accepted Award (9 Applicants listed)

ANDRES, DEVON K
Citizenship: United States
Adviser: Dr. Radharaman Ray
Research Field: A037
Research Title: Evaluation of a Short Peptide Inhibitor to Counteract Botulinum Neurotoxin A (BoNT/A) Poisoning In Vitro and In Vivo

Ph.D. Date: 2006
Oakland University/MI
Actual Starting Date: 5/03/06
Termination Date: 5/02/07

FURTADO, MARCIO D
Citizenship: Brazil
Adviser: Dr. Debra L. Yourick
Research Field: 1829
Research Title: Evaluation of the Effects of Neuroprotectants in a Model of Seizure Induced by Organophosphorous Compounds

Ph.D. Date: 2003
Sao Paulo, U
Actual Starting Date: 9/25/06
Termination Date: 9/24/07

HONKO, ANNA N
Citizenship: United States
Adviser: Dr. Lisa E. Hensley
Research Field: A033
Research Title: Optimization of a Recombinant Vaccine against Marburg Virus in Nonhuman Primates

Ph.D. Date: 2005
Wake Forest University/NC
Actual Starting Date: 6/01/06
Termination Date: 5/31/08

KEYSER, BRIAN M
Citizenship: United States
Adviser: Dr. Radharaman Ray
Research Field: 2969
Research Title: Characterization of Apoptotic Pathways Induced by Sulfur Mustard in Pulmonary Airway Epithelial Cells: In Vitro Studies

Ph.D. Date: 2006
Tulane Univ-Sch of Medicine/LA
Actual Starting Date: 5/04/06
Termination Date: 5/03/07

LIEPINSH, DMITRY
Citizenship: Latvia
Adviser: Dr. Urszula Krzych
Research Field: 3293
Research Title: Characterization of Hepatic Effector and Memory CD8+T Cells induced with Genetically Attenuated Plasmodium berghei Sporozoites in Murine Model of Protective Immunity.

Ph.D. Date: 2003
Russian Academy of Medical Sci
Actual Starting Date: 4/18/06
Termination Date: 4/17/08

ROCHON, GILBERT L		Ph.D. Date: 1999
Citizenship:	United States	Massachusetts Inst of Technology
Adviser:	Dr. Samuel K. Martin	
Research Field:	2820	
Research Title:	Satellite Remote Sensing and Spatial Database Development in Support of Monitoring and Mitigating Incidence of Avian Influenza	

Recommended Candidates 1/24/2006 - 1/23/2007
U.S. Army Medical Research and
Materiel Command

Attachment 2

4/30/2007 Page 3 of 5

May 2006

A- Accepted Award (3 Applicants listed)

MCGANN, PATRICK T	Ph.D. Date: 2004
Citizenship: Ireland	Ireland, Natl U Of
Adviser: Dr. Apurba K. Bhattacharjee	Actual Starting Date: 1/08/07
Research Field: 2740	Termination Date: 1/07/08
Research Title: Survival and Replication of Francisella tularensis in Macrophage	
TAKHAMPUNYA, RATREE	Ph.D. Date: 2006
Citizenship: Thailand	Mahidol U
Adviser: Dr. Huo-Shu H. Huong	Actual Starting Date: 12/04/06
Research Field: 3297	Termination Date: 12/03/07
Research Title: Assessing the Potential Attenuation Mutations and Genetic Stability of WRAI/GSK Attenuated Dengue Vaccines Recovered from Human Volunteers and Aedes aegypti Vector in Dengue Endemic Areas	
URSO, MARIA L	Ph.D. Date: 2006
Citizenship: United States	U of Massachusetts-Amherst
Adviser: Dr. Edward J. Zambraski	Actual Starting Date: 7/10/06
Research Field: 2826	Termination Date: 9/21/06
Research Title: Effects of Prior Injury on Skeletal Muscle Inflammatory Pathways in Response to Disuse and Reloading	

8- Declined

AMITAI, GABRIEL	Ph.D. Date: 1981
Citizenship: Israel	Weizmann Inst of Science/Israel
Adviser: Dr. Charles B. Millard	
Research Field: 0999	
Research Title: Engineering Cell-Free and Polymer-Bound a/b Hydrolase Haloalkane Dehalogenases in Combination with other Enzymes for the Enhanced Catalytic Scavenging of Xenobiotics	

August 2006

A- Accepted Award (3 Applicants listed)

ENTERLEIN, SVEN G	Ph.D. Date: 2005
Citizenship: Germany	Marburg, Univ of/Germany
Adviser: Dr. Sina Bavari	Actual Starting Date: 12/18/06
Research Field: 3298	Termination Date: 12/17/07
Research Title: Mutational Analysis of the Structure Function Relationship of Ebola Virus Matrix Protein VP40	
HAMMERBECK, CHRISTOPHER D	Ph.D. Date: 2006
Citizenship: United States	University of Minnesota-Twin Cit
Adviser: Dr. Jay W. Hooper	Actual Starting Date: 4/10/07
Research Field: A033	Termination Date: 4/09/08
Research Title: Elucidating the Role of Cell-Mediated Immunity in the Pathogenesis of Hantavirus Infection Using the Andes Virus/Hamster Lethal Disease Model	

Recommended Candidates 1/24/2006 - 1/23/2007
U.S. Army Medical Research and
Materiel Command

Attachment 2

4/30/2007 Page 4 of 5

August 2006

A- Accepted Award (3 Applicants listed)

LING, YUN	Ph.D. Date: 2006
Citizenship: People's Republic of China	U of Maryland-Baltimore County
Adviser: Dr. Ashima Saxena	Actual Starting Date: 12/04/06
Research Field: 2969	Termination Date: 12/03/07
Research Title: Mutagenesis and Computational Investigations of Reactivation Mechanism of Nerve Agent-Inhibited Human Acetylcholinesterase by Oximes	

November 2006

1- Recommended (2 Applicants listed)

ACKERMAN, MICHAEL S	Ph.D. Date: 2003
Citizenship: United States	Johns Hopkins U-Medical Insts./MD
Adviser: Dr. Charles B. Millard	
Research Field: 8046	
Research Title: Disruption of a Putative Vascular Leak Peptide Motif in the Ricin Toxin A-Chain Vaccine Candidate	

HATHAWAY, KYLE C	Ph.D. Date: 2006
Citizenship: United States	Melbourne, U
Adviser: Dr. Rodney L. Coldren	
Research Field: A008	
Research Title: Developing Improved Methods for the Recombinant Expression of Avian Influenza Surface Antigens	

A- Accepted Award (4 Applicants listed)

BANKS, ERIC A	Ph.D. Date: 2007
Citizenship: United States	U of Tex-Hlth Sci Ct-San Antonio
Adviser: Dr. Thomas J. Walters	Expected Starting Date: 5/01/07
Research Field: 0999	Termination Date: 4/30/08
Research Title: PPAR Agonists as Potential Therapeutics for Muscle Atrophy Associated with Major Burn Injury	

BIGGINS, JULIA E	Ph.D. Date: 2007
Citizenship: United States	Baylor College of Medicine/TX
Adviser: Dr. Sina Bavari	Actual Starting Date: 3/19/07
Research Field: 3298	Termination Date: 3/18/08
Research Title: The Role of Host Proteins Incorporated into the Ebola Virus Envelope in Enhanced Infectivity	

OTTO, TAMARA C	Ph.D. Date: 2001
Citizenship: United States	University of Florida
Adviser: Dr. David E. Lenz	Actual Starting Date: 3/01/07
Research Field: 1880	Termination Date: 2/29/08
Research Title: Mutations in Human Paraoxonase 1: Design of a Bioscavenger	

Recommended Candidates 1/24/2006 - 1/23/2007
U.S. Army Medical Research and
Materiel Command

Attachment 2

4/30/2007 Page 5 of 5

November 2006

A- Accepted Award (4 Applicants listed)

SILLERJACKSON, ARLENE J	Ph.D. Date: 2006
Citizenship: United States	U of North Tex, Health Science Ct
Adviser: Dr. Phillip D. Bowman	Expected Starting Date: 5/01/07
Research Field: 2990	Termination Date: 4/30/08
Research Title: Determination of the Temporal Presence of Growth Factors in Healing and Nonhealing Bone Defects	

W- Withdrew after Review/Recommend

MUJER, CESAR V	Ph.D. Date: 1989
Citizenship: United States	Ohio State University
Adviser: Dr. M. S. Ibrahim	
Research Field: A072	
Research Title: Proteomic Analysis of Orthopoxvirus and Host Response Proteins and Development of Interfering RNA Therapeutics	

U.S. Army Medical Research and Materiel Command

Curtis, Kristopher Michael

8/15/2003 10/06/2006

- 1 Infection of non-human primates (NHP) with wild-type and infectious clone derived EBOV is indistinguishable.
- 2 EBOV glycoprotein editing site mutations are not well tolerated and revert to wild-type upon infection of NHP's.
- 3 EBOV glycoprotein cleavage site mutations reveal that this site may not be an ideal target for antiviral strategies.

Dupuy, Lesley Conrad, Jr

5/02/2003 7/01/2006

- 1 Individual DNA vaccines expressing the structural proteins of Venezuelan (VEEV), eastern (EEEV), and western (WEEV) equine encephalitis virus are immunogenic in mice following particle bombardment (gene gun) delivery.
- 2 The VEEV and WEEV DNA vaccines delivered in this manner confer protective immunity against homologous viral aerosol challenge in ~80% of vaccinated mice, while the EEEV DNA vaccine is not protective.
- 3 The immunogenicity and protective efficacy of these individual DNA vaccines is not significantly altered when they are delivered in combination by gene gun.
- 4 Cationic lipid and liquid jet injection are viable alternatives to the gene gun for delivery of the VEEV DNA vaccine, while delivery of this vaccine by transcutaneous chemical, microneedle injection, and skin dermabrasion is not as efficacious.
- 5 Certain encephalitic alphavirus envelope glycoprotein variants created by directed molecular evolution (gene shuffling) displayed increased cross-reactivity against VEEV, EEEV, and WEEV and offered complete protection against VEEV aerosol challenge.

Foley, Desmond Hector

2/17/2004 9/16/2006

- 1 A molecular phylogeny of the Australasian Anopheles annulipes complex showed it was monophyletic, comprised a cool adapted southern clade and warm adapted northern clade, and is the most species-rich Anopheles complex, with over 17 sibling species
- 2 A novel Bayesian clustering approach, using the program STRUCTURE, was applied to allozyme data of the Anopheles annulipes complex to demonstrate its utility for detecting species-level genetic divergence, as well as population structure.
- 3 The WRBU's online Systematic Catalog revealed new findings about mosquito biogeography, such as a positive log-log species-area relationship, and that island nations are more species-rich and have higher endemism than do mainland nations.
- 4 Analysis of a database of over 43,000 mosquito collection records and 492 species from the Neotropics revealed the location of hotspots in species-richness and endemism and suggested areas where mosquito inventory needs are greatest.
- 5 Ecological Niche modelling of collection records revealed the potential distribution of malaria vectors in Korea and SE Asia. A website, www.mosquitomap.org is being developed to host global mosquito occurrence data and distribution maps.

Fritz, Elizabeth Ann

3/03/2003 9/02/2006

- 1 Identified changes in the cellular immune response and identified viral targeted cell populations in Variola-infected nonhuman primates--first study known.
- 2 Identified and tested a successful alternate route of exposure for refinement of the Monkeypox nonhuman primate model.
- 3 Identified changes in the cellular immune response in Marburg (Ci67)-infected nonhuman primates.
- 4 Identified through evaluation novel therapeutics for filovirus infection--studies are the basis for continuing testing in nonhuman primates.
- 5 Developed and refined cytotoxic T-cell assays for testing vaccines and therapeutics in nonhuman primates.

Goff, Arthur James

8/20/2004 10/31/2006

- 1 We have engineered a cowpox virus expressing the green fluorescent protein (eGFP) under control of vaccinia virus (VV) early/late promoter.
- 2 Using the above mentioned recombinant virus we tested a novel class of drugs for anti-cowpox activity in mice.
- 3 Also using the mouse model of cowpox virus infection, we developed a model for vaccinia-induced myocarditis.
- 4 We also engineered a GFP-expressing Monkeypox virus (MPX-eGFP) that was used in conjunction with whole body fluorescence resonance imaging to develop a disease progression model for intravenous infection of Monkeypox in non-human primates.

U.S. Army Medical Research and Materiel Command

Hoard-Fruchey, Heidi Marie

7/19/2004 4/28/2006

- 1 Stability of BoNT/A and /B recombinant light chains (rLC) was assessed in 7 solutions with greatest stability in intracellular buffer followed by 40 mM HEPES pH 7.3. Both were more stable in water than expected with half-lives of >1 week.
- 2 BoNTA/A rLC stability increases with increasing milkfat, but milkfat content did not affect BoNT/B rLC stability, suggesting lipids play a role in BoNT/A stability and factors contributing to stability may be serotype specific.
- 3 Compound 35 inhibits BoNT/A, /B, and /E LC activities, and is a potential broad range inhibitor of BoNT activity.
- 4 Two derivatives of compound 35 also inhibit BoNT/A and BoNT/B activity, suggesting that derivatives of compound 35 may be useful for treatment of BoNT intoxication.
- 5 In collaboration with CPT Angela Purcell, a capillary electrophoresis assay was developed for BoNT/A and /E activity.

Johnson, Erik Andrew

1/03/2005 1/02/2007

- 1 Morris water maze (MVM) is not good behavioral model for repeated, low dose soman or sarin exposure.
- 2 Repeated, low dose exposures to soman do not lead to cytoskeletal or synaptic derangements nor does this exposure paradigm result in increased apoptosis in hippocampus or parietal cortex.
- 3 Repeated, low dose exposures to soman does lead to significant changes in glutamate receptor immunoreactivity though the ramifications of this are not fully known.
- 4 Characterized sixteen different antibodies for cross-species immunoreactivity in guinea pigs and wrote protocols to describe the process.
- 5 Acute exposure to soman reveals no significant changes in synaptic or certain cytoskeletal protein immunoreactivities though significant changes were observed in neuron and astrocyte-specific proteins.

Klas, Sheri Denet

12/06/2004 2/28/2006

- 1 Identified two different HLA-A2 restricted CTL epitopes from Yersinia pestis
- 2 Discovered which human cell types can be infected by Yersinia pestis

Kremenevskiy, Igor

9/06/2005 9/01/2006

- 1 We finished the model development phase. There were tested respiratory and metabolic acidosis models in pigs. It was confirmed some previously established procedures concerning anesthesia, catheters, and monitoring of hemodynamics.
- 2 Our experiments showed respiratory as well as metabolic acidosis induced the development of coagulopathy in the pigs. The restoration of pH did not restore blood coagulation.
- 3 Adding rFVIIa to pig plasma in vitro in dose 1.26ug/ml final plasma concentration increased the maximal thrombin generation, however it did not completely correct coagulopathy.
- 4 It was studied the effects different fluid solutions (Hextend and Lactated Ringer) on coagulation function of normal and hypothermic human plasma in vitro with and without 90ug/kg rFVIIa (1.26ug/ml final plasma concentration).
- 5 We modified the thrombin generation test (developed by Hemker H.C. et al. 1993; 2003). this assay is suitable for detecting treatment-depending changes in the kinetic of thrombin generation and monitoring the pharmacokinetics of rFVIIa.

Langston, Jeffrey Lamar

5/12/2003 5/11/2006

- 1 Repeated exposure to CWNA at doses that produce behavioral effects often also induces overt toxicity. Doses of CWNA that produce overt toxicity may produce behavioral alterations that persist months after exposure.
- 2 Guinea pigs are suitable subjects for evaluating of the behavioral effects of drugs and toxicants. Guinea pigs do not seem to perform well in tasks that require the animal to travel in open spaces (i.e., radial arm maze, open field).
- 3 Conducted dose-response study of GB with animals performing under progressive ratio schedule. Conducted dose-response study of VX with animals performing under progressive ratio schedule. Evaluated ability of animals to learn new task after VX.
- 4 Guinea pigs perform qualitatively similar to other rodent species on a variety of operant behavior tasks including: active avoidance, multiple schedules of reinforcement, simple schedules of reinforcement, delayed matching and discrimination.

U.S. Army Medical Research and Materiel Command

Miroshnikova, Olga Vyatcheslavovna

2/25/2003 2/24/2006

- 1 Designed and synthesized novel anti-malarial drugs.
- 2 Conducted multiple-step synthesis of Michal acceptor-based peptidomimetic inhibitors.
- 3 Improved existing methods of peptide synthesis to optimize product yield and selectivity.
- 4 Developed new approaches to overcome Mitsunobu reaction separation problem of the final product from by-product.
- 5 Investigated Structure-Activity Relationship of compounds obtained.

Pearson, Brooke

7/14/2003 10/13/2006

- 1 We determined the extent of the antibody response to the three components of the anthrax toxin: PA, LF, and EF.
- 2 I have demonstrated that these antibodies are capable of blocking serum conversion of the full-length protective antigen (PA) to its active form.
- 3 These antibodies can also block the binding of full-length PA to the surface of cells.
- 4 I also demonstrated that the antibodies are able to block the cleavage of PA after it is already bound to cells.
- 5 Additionally, we demonstrated that antisera inhibits the enzymatic activity of the LF toxin.

Silvestri, Lynn Shiels

9/07/2004 1/31/2006

- 1 Effective siRNA against components of the Ebola and Marburg polymerase complexes (L, VP35, VP30, and NP) were identified.
- 2 siRNAs were evaluated by Western blot after transfection of cells with siRNA and expression vectors. Transfection of cells with siRNA in various combinations followed by virus infection was effective in reducing virus titers.
- 3 Transfection of siRNA into mice by hydrodynamic shear did not protect mice from death from Ebola virus infection.
- 4 The amount of siRNA used, the delivery method, and lack of siRNA chemical modification for in vivo delivery likely contributed to the mouse study results.

Tonduli, Laura Sabina

2/17/2004 12/15/2006

- 1 We build up a reliable and reproducible ex vivo method that mimics the in vivo situation of a subject pretreated with cholinesterase reversible inhibitors and then exposed to organophosphate agents (OPS).
- 2 With this method, we determined for 5 pretreatments (pyridostigmine, physostigmine, huperzine, tacrine and galanthamine) with kinetics of inhibition and recovery of cholinesterases activities after various OPs exposures (MEPQ or DEPQ or soman).
- 3 We compared these inhibitors between them to determine which one seem to be the more efficient when used a pretreatment of a nerve agent intoxication.
- 4 We also determined the tissue distribution of exogenous human serum butyrylcholinesterase after intra muscular administration.

Urso, Maria Laina

7/10/2006 9/21/2006

- 1 Refined Research proposal and learned additional laboratory techniques necessary to execute proposed experimental design.
- 2 Submitted a research proposal to the Scientific Review Committee to conduct a pilot experiment on pre-existing human samples. The purpose of this work is to explore the effects of muscle injury (due to resistance exercise) on protease activity.

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

National Research Council

JA
Fiscal

AK
PA

AF
Drop

Research Associateship Programs

FINAL REPORT

Print Layout View

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
Curtis		Kristopher	M
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst. Residential		Home Phone:	
Street 795 Eastern Avenue		Alt. Phone: 301-514-7749	
City, State Zip Augusta, ME 04330		E-mail: kmccis@verizon.net	
3) Today's Date		Dates of Tenure	
September 6, 2006		from August 14, 2003 to October 6, 2006	
4) Agency	Laboratory or Center	Division / Directorate / Department	
AMRMC	USAMRIID	Virology	
5) Name of Laboratory NRC Adviser (and USMA Mentor, if applicable)			
Dr. Michael Parker			

6) TITLE OF RESEARCH PROPOSAL

Utilization of an Ebola Virus Reverse Genetics System to Identify Critical Mechanisms in Disease Pathogenesis

7) SUMMARY OF RESEARCH DURING TENURE

Itemize significant findings in concise form, utilizing key concepts/words.


- 1) Infection of non-human primates (NHP) with wild-type and infectious clone derived EBOV is indistinguishable
- 2) EBOV glycoprotein editing site mutations are not well tolerated and revert to wild-type upon infection of NHPs
- 3) EBOV glycoprotein cleavage site mutations reveal that this site may not be an ideal target for antiviral strategies
- 4)
- 5)

(USMA Davies Fellow: please add summary of teaching, including classes taught.)

8) RESEARCH IN PROGRESS

Describe in no more than 100 words.

For the purposes of in vitro replication and in vivo pathogenesis studies, work was initiated towards the construction of EBOV encoding green fluorescent protein. Additionally, recombinant viruses encoding mutations in the immunosuppressive and mucin-like domains of the glycoprotein were planned to evaluate their role in viral pathogenesis. This work is in the early stages of development. A mucin-like domain mutant has been constructed, but has not yet been recovered from the infectious clone system, while strategies for generating the immunosuppressive domain mutant are ongoing.



9) *PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

Elizabeth A. Fritz, Lisa E. Hensley, David Kulesh, Kristopher Curtis, Tom Geisbert, Peter B. Jahrling, Jason Paragas. detection of the L polymerase gene by one-step real-time PCR—a novel diagnostic method for Ebola-Zaire infection. Manuscript in preparation.

Zhongyu Zhu¹, Samitabh Chakraborti¹, Xiaodong Xiao, Yuxian He, Ponraj Prabakaran, Igor A. Sidorov, Lisa E Hensley, Yang Feng¹, Kristopher M Curtis, Shibo Jiang, and Dimiter S. Dimitrov. Potent Neutralization of SARS Coronavirus Isolates by a Cross-Reactive Human Monoclonal Antibody. Manuscript in preparation for submission to PNAS

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*

Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Domestic

Geisbert TW, Hensley LE, Curtis KM, Geisbert JB, Lee M, Palmer L, Jeffs L, MacLachlan I. Development of an siRNA Based Therapy for Ebola Virus Infection. 8th Annual Meeting of the American Society of Gene Therapy, St. Louis, MO, June 1-5, 2005.

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

14) POST-TENURE POSITION TITLE

Research Scientist I

15) POST-TENURE ORGANIZATION Provide name and address of organization.

IDEXX, One IDEXX Dr., Westbrook ME 04092

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☐ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center _____ | ☒ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM

On a scale of 1 – 10 (poor – excellent), please rate the following:

SHORT TERM VALUE

7 Development of knowledge, skills, and research productivity

Comments

The NRC program provides a great opportunity for post-doctoral research. I feel as though I was given an opportunity to work in a unique environment.

LONG TERM VALUE

7 How the National Academies Associateship award affected your career to date

Comments

LAB SUPPORT

5 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.

Comments

The environment at USAMRIID, and my lab in particular, was not very conducive for post-doctoral research. However, this has little to do with the NRC program itself. There is a total lack of communication and collaboration within USAMRIID, both between laboratories and with the NRC itself. This often leads to a feeling of isolation.

ADVISER/MENTOR SUPPORT

3 Quality of mentoring from the Lab NRC Adviser (USMA Mentor, if applicable)

Comments

This rating is specific to Dr. Tom Geisbert, as he gave very limited mentorship during my NRC tenure at USAMRIID. I have recently learned that Dr. Geisbert received his Ph.D. the same year I received mine (2003), and I believe this explains his deficiencies with respect to mentorship. His lack of experience supervising personnel and serving as a mentor has really put the post-docs in his lab at a disadvantage.

I would rate Mike Parker, who recently became my advisor, as an 8.

LPR SUPPORT

☐ Quality administrative support from the LPR

Comments

NRC SUPPORT

10 Quality of administrative support from the NRC

Comments

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

I would agree that it is the job of NRC associates to screen prospective mentors and choose a mentor wisely, but I think some scrutinizing of potential NRC advisors by the NRC would help prevent negative experiences.

US Postal Service mailing address

Research Associateship Programs

The National Academies

500 Fifth Street NW

Washington, DC 20001

THIS FORM SHOULD BE E-MAILED

directly to your NRC coordinator

website

www.national-academies.org/rap

Express Delivery address

Research Associateship Programs

The National Academies

2001 Wisconsin Avenue, NW [GR 322A]

Washington, DC 20007

n:\AO Forms

ID#

0380170

cc:

Research Associateship Programs

Rev. 08/2006

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Research Associateship Programs

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
Dupuy, Jr.		Lesley	C.
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst. Res.		Home Phone: 301-305-6863	
Street 902 Gatepost Lane #3C		Alt. Phone: 301-619-4109	
City, State Zip Frederick, MD 21701		E-mail: lesley.dupuy@amedd.army.mil	
3) Today's Date		Dates of Tenure	
June 26, 2006		from May 2, 2003 to June 30, 2006	
4) Agency	Laboratory or NASA Center	Division / Branch / Directorate	
AMRMC	AMRIID	Virology	

5) Name of Research Associateship Programs Adviser

Connie S. Schmaljohn

6) TITLE OF RESEARCH PROPOSAL

Evaluation Of Multivalent DNA Vaccine Strategies For Encephalitic Alphavirus Immunization

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Individual DNA vaccines expressing the structural proteins of Venezuelan (VEEV), eastern (EEEV), and western (WEEV) equine encephalitis virus are immunogenic in mice following particle bombardment (gene gun) delivery.
- 2) The VEEV and WEEV DNA vaccines delivered in this manner confer protective immunity against homologous viral aerosol challenge in ~80% of vaccinated mice, while the EEEV DNA vaccine is not protective.
- 3) The immunogenicity and protective efficacy of these individual DNA vaccines is not significantly altered when they are delivered in combination by gene gun.
- 4) Cationic lipid and liquid jet injection are viable alternatives to the gene gun for delivery of the VEEV DNA vaccine, while delivery of this vaccine by transcutaneous chemical, microneedle injection, and skin dermabrasion is not as efficacious.
- 5) Certain encephalitic alphavirus envelope glycoprotein variants created by directed molecular evolution (gene shuffling) displayed increased cross-reactivity against VEEV, EEEV, and WEEV and offered complete protection against VEEV aerosol challenge.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

Several research projects have been started during my tenure as an NRC Associate which will be continued as I transition into an investigator role at my host institution. These include continued evaluation of the immunogenicity and protective efficacy of individual and combined DNA vaccines for VEEV, EEEV, and WEEV in mouse and nonhuman primate models of infection; continued evaluation of different delivery mechanisms for VEEV, EEEV, and WEEV DNA vaccines including cationic lipid, electroporation, and liquid jet injection delivery; and, evaluation of gene-shuffled EEEV and WEEV envelope glycoprotein variants for improved cross-reactivity, immunogenicity, and protective efficacy.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

Dupuy, L.C., Paidhungat, M., Richards, M., Lind, C., Bakken, R., Whalen, R.G., Locher, C.P., and Schmaljohn, C.S. (2006) Improvement of the Immunogenicity and Protective Efficacy of DNA Vaccines Expressing the Venezuelan Equine Encephalitis Virus Envelope Antigens by using Directed Molecular Evolution. In preparation.

Dupuy, L.C., Paidhungat, M., Richards, M., Lind, C., Bakken, R., Whalen, R.G., Locher, C.P., and Schmaljohn, C.S. (2006) Comparison of Individual, Combination, and Gene-shuffled Chimeric DNA Vaccines for Venezuelan, Eastern, and Western Equine Encephalitis Viruses in Mice. In preparation.

Dupuy, L.C., Richards, M., Lind, C., Bakken, R., Whalen, R.G., Locher, C.P., and Schmaljohn, C.S. (2006) DNA Prime and Recombinant E2 Envelope Protein Fragment Boost Strategy Enhances the Immunogenicity and Protective Efficacy of an Eastern Equine Encephalitis DNA Vaccine in Mice. In preparation.

Dupuy, L.C., Paidhungat, M., Richards, M., Lohre, J.A., Kuznetsova, M.A., Silvera, P., Draghia, R., Whalen, R.G., Locher, C.P., and Schmaljohn, C.S. (2006) Characterization of the Immune Responses Induced by Electroporation of Wild-type and Gene-shuffled Chimeric DNA Vaccines Expressing the Venezuelan Equine Encephalitis Envelope Antigens in Cynomolgus Macaques. In preparation.

Dupuy, L.C., Spik, K., Badger, C., Richards, M., Bakken, R., Morrow, J., Rusalov, D., Ferrari, M., and Schmaljohn, C.S. (2006) Vaxfectin Cationic Lipid-mediated Delivery of Individual and Combined DNA Vaccines Expressing Antigens from Venezuelan Equine Encephalitis Virus, Rift Valley Fever Virus, and Ebola Virus. In preparation.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

L. Dupuy, M. Paidhungat, M. House, R.G. Whalen, C.P. Locher, and C. Schmaljohn. (2004) Evaluation of Strategies for Developing a Multivalent DNA Vaccine for Encephalitic Alphaviruses. DNA Vaccines 2004: The Gene Vaccine Conference, Monte Carlo, Monaco.

Domestic

L. Dupuy, M. Richards, M. Paidhungat, J.A. Lohre, M.A. Kuznetsova, P. Silvera, R. Draghia, R.G. Whalen, C.P. Locher, and C. Schmaljohn. (2005). Improvement in DNA Vaccines for Venezuelan Equine Encephalitis Virus by using Directed Molecular Evolution. 2005 Scientific Conference on Chemical & Biological Defense Research, Timonium, MD.

L.C. Dupuy, M. Paidhungat, M. Richards, R.G. Whalen, C.P. Locher, and C.S. Schmaljohn. (2005) Towards the Development of a Multivalent DNA Vaccine for Encephalitic Alphaviruses. XIII International Congress of Virology, San Francisco, CA.

L. Dupuy, M. Paidhungat, M. House, C. Schmaljohn, R.G. Whalen, and C.P. Locher. (2004) Development of a Novel Encephalitic Alphavirus Vaccine using DNA Shuffling and Screening Strategies. 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, FL.

L. Dupuy, M. Paidhungat, J. Lohre, V. Heinrichs, M. House, C. Schmaljohn, R.G. Whalen, and C.P. Locher. (2004) Increased Immunogenicity and Neutralizing Antibodies to Alphaviruses using Genetic Vaccination with a DNA Vaccine Containing a Constitutive Transport Element. 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami, FL.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

14) *POST-TENURE POSITION TITLE*

Principal Investigator

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

U.S. Army Medical Research Institute of Infectious Diseases
Virology Division
1425 Porter Street
Fort Detrick, MD 21702

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☒ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center AMRIID | |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Industry |
| ☐ Administrative Position at US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Research Position at Foreign Government Laboratory | ☐ Postdoctoral Research |
| | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

☒ 9 Development of knowledge, skills, and research productivity

Comments

My NRC Research Associateship at AMRIID provided me with an excellent opportunity to expand my knowledge and research skills into the area of vaccine development for highly pathogenic viruses with a focus on DNA vaccines. It also allowed me to improve my project management ability as I coordinated multiple research projects and was responsible for interaction with collaborating partners from industry.

LONG TERM VALUE

☒ 9 How the National Academies Associateship award affected your career to date

Comments

This award provided me with the opportunity to perform research in a top-notch government laboratory setting and has helped to steer my career in the direction of government research. I will continue to pursue research as an investigator at my host institution following completion of my associateship.

LAB SUPPORT

☒ 9 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.

Comments

There was no lack of equipment or funding support during my tenure at my host institution and laboratory. I was provided with the opportunity to learn to safely perform research on highly pathogenic viruses requiring high level biosafety containment.

ADVISER SUPPORT

☒ 9 Quality of mentoring from the Adviser

Comments

My advisor was fully supportive of my research endeavors during my associateship. She provided me with the proper level of expert guidance while allowing me adequate room to pursue the research to the fullest levels of my ability without unnecessary restriction.

LPR SUPPORT

☒ 9 Quality administrative support from the LPR

Comments

The LPR was fully supportive of my research during my associateship. He provided me with the administrative support necessary for seamless integration into my host institution during my tenure.

NRC SUPPORT

☒ 9 Quality of administrative support from the NRC

Comments

The NRC provided excellent support during my tenure and was always very helpful in assisting me in all administrative matters related to my associateship.

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

I feel that the NRC Research Associateship Program represents one of the best, if not the very best, postdoctoral research programs available. Therefore, I have no obvious suggestions for program improvement.

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator
website
www.national-academies.org/rap

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms
ID#

0380480

cc: Research Associateship Programs

Rev. 08/2005
cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Research Associateship Programs

FINAL REPORT

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Emerson		First Name Ginny	M.I. L
2) FORWARDING Address (for tax statement / final stipend check) 2910 Clairmont Rd. Apt 2325, Atlanta GA 30329		FORWARDING Phone(s) and E-Mail (if known) Home phone: (202) 421-3380 Alt. phone: E-mail: ginny.emerson@alumni.gwu.edu	
3) Today's Date April 12, 2006		Dates of Tenure from March 1, 2004 to April 14, 2006	
4) Agency AMRMC	Laboratory USAMRIID	or NASA Center	Division / Branch / Directorate Virology / Integrated Toxicology
5) NAME OF RESEARCH ADVISER Sofi Ibrahim / Robert Ulrich			
6) TITLE OF RESEARCH PROPOSAL			

Poxvirus genomics

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1)
- 2)
- 3)
- 4)
- 5)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

My current work with Dr. Ulrich involves the use of whole proteome microarray chips of poxviruses to profile humoral responses to vaccines. Identifying viral antigens commonly recognized by antibodies of vaccinated individuals is an important step toward understanding of the humoral immune response to disease. This can be achieved by visualizing serum antibodies bound to viral antigens on a chip. Once defined, these proteins may act as correlates of immunity in testing new vaccines and provide new targets for vaccine development.

9) PUBLICATIONS AND PAPERS RESULTING FROM THE NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

None

b) Books, book chapters, other publications

None

c) Manuscripts in preparation, manuscripts submitted

I am currently involved in preparing a manuscript with Dr. Robert Ulrich and others regarding serum antibody profiling of human smallpox vaccinees using a whole proteome chip of vaccinia virus.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM THE NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

None

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

None

Domestic

We will be presenting a poster on the above mentioned work (manuscripts in prep) at the upcoming research festival held here at Ft. Detrick.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

None

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

None

14) *POST-TENURE POSITION TITLE*

Biologist/ Ecologist

15) *POST-TENURE ORGANIZATION* Provide name and city of organization.

Centers for Disease Control and Prevention, Atlanta GA

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- ☐ Remain at Host Agency as Permanent Employee
☐ Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center _____
☒ Research Position at Another US Government Laboratory
☐ Administrative Position at US Government Laboratory
☐ Research Position at Foreign Government Laboratory

- ☐ Research/Teaching at US College/University
☐ Research/Teaching at Foreign College/University
☐ Research/Administration in Industry
☐ Research/Admin in Non-Profit Organization
☐ Postdoctoral Research
☐ Self Employed
☐ Other: specify _____

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

- 7.00 Development of knowledge, skills, and research productivity
Comments

I basically lost 23 months of productivity with my first adviser. Fortunately, I learned alot on my own and the 10 weeks with Dr. Ulrich have been pleasantly productive.

LONG TERM VALUE

- 8 How the National Academies Associateship award affected your career to date
Comments

I think the award itself is a an asset to my career, as well as the experience with Dr. Ulrich.

LAB SUPPORT

- 9 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments

My initial situation was a bit of a travesty, but my current environment is very good (leading edge, forward thinking, enthusiastic about incorporating new technology and new techniques).

ADVISER SUPPORT

- 9 Quality of mentoring from the Adviser
Comments

Mentoring from my first adviser was deplorable, however Dr. Ulrich has been outstanding.

LPR SUPPORT

- 8 Quality administrative support from the LPR
Comments

The LPR found a new adviser for me to work with (quite singlehandedly) and I am very grateful, however I am disappointed that more was not done to protect future associates from ending up in the same situation.

NRC SUPPORT

- 10 Quality of administrative support from the NRC
Comments

The administrative staff has always been very helpful, courteous and supportive.

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

Perhaps enhanced screening of advisers would ensure a better experience for future associates. Unfortunately, local politics outside the purview of the NRC undoubtedly play a role in sustaining the tenure of certain individuals.

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

You may E-MAIL this form directly to your NRC Coordinator.

website
www.national-academies.org/rap
Research Associateship Programs

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms
ID#

cc:

Rev. 08/2005
cost-center #

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
Foley		Desmond	H
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst. Res.		Home Phone:	
Street 5 Cougar St		Alt. Phone: +61 2 66 543476	
City, State Zip Indooroopilly, Qld 4068 Australia		E-mail: notoscriptus@yahoo.com.au	
3) Today's Date		Dates of Tenure	
September 28, 2006		from February 16, 2004 to September 16, 2006	
4) Agency	Laboratory or NASA Center	Division / Branch / Directorate	
AMRMC	WRAIR		

5) Name of Research Associateship Programs Adviser

Dr Richard C. Wilkerson

6) TITLE OF RESEARCH PROPOSAL

Systematics of the Anopheles annulipes complex of mosquitoes

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) A molecular phylogeny of the Australasian Anopheles annulipes complex showed it was monophyletic, comprised a cool adapted southern clade and warm adapted northern clade, and is the most species-rich Anopheles complex, with over 17 sibling species
- 2) A novel Bayesian clustering approach, using the program STRUCTURE, was applied to allozyme data of the Anopheles annulipes complex to demonstrate its utility for detecting species-level genetic divergence, as well as population structure.
- 3) The WRBU's online Systematic Catalog revealed new findings about mosquito biogeography, such as a positive log-log species-area relationship, and that island nations are more species-rich and have higher endemism than do mainland nations.
- 4) Analysis of a database of over 43,000 mosquito collection records and 492 species from the Neotropics revealed the location of hotspots in species-richness and endemism and suggested areas where mosquito inventory needs are greatest.
- 5) Ecological Niche modelling of collection records revealed the potential distribution of malaria vectors in Korea and SE Asia. A website, www.mosquitomap.org is being developed to host global mosquito occurrence data and distribution maps.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

Continuation of Ecological Niche modelling of collection records from Korea, SE Asia and Costa Rica. Continued development of www.mosquitomap.org to include collection data from Australasia and Africa. Extension of Lucid computer key of Queensland mosquitoes to encompass mosquitoes of Australia.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.


a) Publications in peer-reviewed journals

- Foley, D.H., Bryan, J.H. & Wilkerson, R.C. (in press). Species-richness of the Anopheles annulipes complex (Diptera: Culicidae) revealed by tree and model-based allozyme clustering analyses. Biol. J. Linn. Soc.
- Foley, D.H., Wilkerson, R.C., Cooper, R.D. & Bryan, J.H. (in press). A molecular phylogeny of Anopheles annulipes (Diptera: Culicidae) sensu lato; the most species-rich anopheline complex. Mol. Phyl. & Evol.

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

- Boyd, A-M. & Foley, D.H. (submitted). Distribution of sibling species of the Anopheles annulipes complex (Diptera: Culicidae) in the Townsville region of Australia. J. Aust. Entomol. Soc.
- Foley, D.H. & Wilkerson, R.C. (in prep.). Visualizing potential barriers to gene flow via digital genetic landscapes.



- Rueda, L.P., Foley, D.H., Peterson, T. and Wilkerson, R.C. (in prep.). Geographic and Ecological distribution of the malaria vector, *Anopheles sinensis*.
- Foley, D.H., Rueda, L.M. and Wilkerson, R.C. (in prep.). Insights into mosquito global biogeography from country species records.
- Foley, D.H., Wietzman, A., Miller, S., Faran, M.E., Rueda, L.M. and Wilkerson, R.C. (in prep.). Towards a worldwide spatial database of mosquito species occurrence records: mosquitoes of the Neotropics.
- Foley, D.H. (in prep.). Species delimitation by Bayesian clustering of individual genotype data.
- Foley, D.H., Rueda, L.M., Peterson, A.T. and Wilkerson, R.C. (in prep.). Potential distribution of four Southeast Asian malaria vectors according to Ecological Niche Modelling.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

- Foley, D.H. & Torres, E.P. (2005). Population structure of an island malaria vector. European Molecular Biology Organization, Mosquito workshop. 25-30 July, Kolymbari, Crete, Greece.
- Torres, E.P., Foley, D.H., Kemp, D., Fischer, K. Pinto, J. & Bryan, J. (2005). Population genetic structure of the Philippine malaria vector, *Anopheles flavirostris*. European Molecular Biology Organization, Mosquito workshop. 25-30 July, Kolymbari, Crete, Greece.

Domestic

- Foley, D.H. (2004). Systematics and Malaria vector identification: what is "appropriate technology"? 22-26 Feb, American Mosquito Control Association Conference. Savannah GA.
- Rueda, L.P., Foley, D.H., Peterson, T. and Wilkerson, R.C. (2005). Geographic and Ecologic distribution of the malaria vector, *Anopheles sinensis* in Korea and other parts of Asia. American Society of Tropical Medicine & Hygiene 54th annual meeting. Dec 11-15, Washington DC. Am. J. Trop. Med. & Hyg. 73(6) (Suppl): 327.
- Foley, D.H. and Wilkerson, R. (2005). The species-rich *Anopheles annulipes* complex. American Society of Tropical Medicine & Hygiene 54th annual meeting. Dec 11-15, Washington DC. Am. J. Trop. Med. & Hyg. 73(6) (Suppl): 327.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

- Foley, D.H. and Wilkerson, R. (2004). Mapping and predicting distributions of mosquito disease vectors. 176th AFPMB Meeting, 14 July, Walter Reed Army Institute of Research, Silver Springs MD.
- Foley, D.H. (2004). Visualizing barriers to gene flow in genetic landscapes. 13 July, Systematic Biology & Molecular Genetics Lab, National Museum of Natural History, Smithsonian Institution, Washington DC
- Foley, D.H. (2005). Know the vector distribution, know the disease threat. Global Emerging Infectious Diseases Surveillance colloquium on Distribution modelling of disease vectors. 20 September. Walter Reed Army Institute of Research, Silver Springs MD.
- Foley, D.H. (2005). The curious case of the ant and the mosquito and other tales of culicid complexity. 1 December. Washington Entomological Society, Washington DC
- Foley, D.H. (2006). NRC Research Associateship report. 20 April. Walter Reed Army Institute of Research, Silver Springs MD.
- Foley, D.H. (2006). The potential of collection data to map the distribution of mosquitoes. 1 August. Armed Forces Pest Management Board, Silver Springs MD.
- Foley, D.H. (2006). GIS and mosquitoes: from gene flow to biogeography. 22 August. USDA Flies affecting Man Laboratories, Gainesville, FL.

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

- Foley DH (2006). Mosquito Marauders of the Ant World. National Geographic Society Exploration Grant. \$16244

14) *POST-TENURE POSITION TITLE*

Research Associate

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

National Museum of Natural History,
Smithsonian Institution

10th & Constitution Avenue NW
Washington DC 20560

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☐ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center _____ | ☐ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☒ Self Employed |
| | ☐ Other: specify _____ |

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

- ☒ Development of knowledge, skills, and research productivity
 Comments

LONG TERM VALUE

- ☒ How the National Academies Associateship award affected your career to date
 Comments

LAB SUPPORT

- ☒ Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
 Comments

ADVISER SUPPORT

- ☒ Quality of mentoring from the Adviser
 Comments

LPR SUPPORT

- ☒ Quality administrative support from the LPR
 Comments

NRC SUPPORT

- ☒ Quality of administrative support from the NRC
 Comments

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

Perhaps the NRC website could add something along the lines of: "Tips and advice from previous NRCs" (with a disclaimer)?

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator
website
www.national-academies.org/rap

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms
ID# 0084830

cc: Research Associateship Programs

Rev. 08/2005
cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Fiscal


PA

slap

Research Associateship Programs

FINAL REPORT

Print Layout View



Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Fritz		First Name Elizabeth	A
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. Elizabeth Fritz Street 34170 Ahalt Drive City, State Zip Bluemont, VA 20135		FORWARDING Phone(s) and E-Mail (if known) Home Phone: 304-724-7997 Alt. Phone: 703-999-2726 E-mail: lizfritz4@yahoo.com	
3) Today's Date September 18, 2006		Dates of Tenure from March 3, 2003 to September 2, 2006	
4) Agency AMRMC	Laboratory or Center USAMRIID	Division / Branch / Directorate Virology	

5) Name of Research Associateship Programs Adviser

Lisa E. Hensley

6) TITLE OF RESEARCH PROPOSAL

Modulation of the immune response during smallpox and monkeypox infections

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Identified changes in the cellular immune response and identified viral targeted cell populations in Variola- infected nonhuman primates--first study known.
- 2) Identified and tested a successful alternate route of exposure for refinement of the Monkeypox nonhuman primate model.
- 3) Identified changes in the cellular immune response in Marburg (Ci67)-infected nonhuman primates.
- 4) Identified through evaluation novel therapeutics for filovirus infection--studies are the basis for continuing testing in nonhuman primates.
- 5) Developed and refined cytotoxic T-cell assays for testing vaccines and therapeutics in nonhuman primates.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

1. Further refinement of alterante routes of exposure for the Monkepox nonhuman primate model.
2. Continuation of evaluating the changes in immune cell populations and host cytokine/chemokine profiles in response to orthopoxvirus infection.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

Yount B., Curtis K.M., Fritz E.A., Hensley L.E., Jahrling P.B., Prentice E., Denison M.R., Geisbert T.W., Baric R.S. Reverse Genetics with a Full-Lengh Infectious cDNA of Severe Acute Respiratory Syndrome Coronavirus. Proceedings of the National Academy of Sciences. October 2003; 100(22):12995-13000.

Hensley L.E., Fritz E.A., Jahrling P.B., Karp C., Huggins J.W., Geisbert T.W. Interferon-beta 1a Potently Inhibits SARS Coronavirus Replication in Vero E-6 Cells. Emerging Infectious Diseases. February 2004; 10(2):317-319.

Jones S.M., Feldmann H., Ströher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.-D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., Geisbert T.W. Live attenuated recombinant vaccine protects non-human primates against Ebola and Marburg viruses. Nature Medicine. July 2005; 11(7):786-90.

Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Ströher U., Fernando L., Daddario K.M., Guttieri M.C., Mothé B.R., Larsen T., Hensley L.E., Jahrling P.B., Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLOS Medicine. June 2005; 2(6):e183.

Lawler J.V., Endy T.P., Hensley L.E., Garrison A., Fritz E.A., Lesar M., Baric R., Kulesh D., Norwood D., Wasieleski L., Ulrich M., Slezak T., Vitalis E., Huggins J., Jahrling P.B., Paragas J. Cynomologus macaque as an animal model for severe acute respiratory syndrome. *PLoS Medicine*. May 2006; 3(5):e149.

Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, Feldmann H. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. *Lancet*. 2006 Apr 29;367(9520):1399-404.

Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. *J Infect Dis*. 2006 Jun 15;193(12):1650-7.

Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine. *J Virol*. 2006 Oct;80(19):9659-66.

b) Books, book chapters, other publications

P.B. Jahrling, Fritz E.A., Hensley L.E. Countermeasures to the Bioterrorist Threat of Smallpox. *Current Molecular Medicine*. Invited Review. *Current Molecular Medicine*. 2005; 5:817-826.

c) Manuscripts in preparation, manuscripts submitted

Fritz E.A., Reed D., Daddario K.M., Geisbert J.B., Larsen T., Jahrling P.B., Geisbert T.W. Hensley L.E., Flow Cytometric Analysis of Marburg Virus Pathogenesis in Nonhuman Primates. Manuscript in preparation.

Fritz E.A., Rubins K.A., Fisher R.F., Raymond J., Larsen T., Huggins J., LeDuc J., Jahrling P.B., Hensley L.E. Identification of changing cell populations and virus-targeted cell populations during smallpox pathogenesis in nonhuman primates. Manuscript in preparation.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*

Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

L.E. Hensley, H.A. Young, J. Paragas, T. Larsen, D. Reed, R. Fisher, E.A. Fritz, J. Geisbert, C.L. Karp, P.B. Jahrling, and T.W. Geisbert. Pathogenesis of Ebola Hemorrhagic Fever: the Impact of Viral Infection of Dendritic Cells and Other Antigen Presenting Cells. XII International Conference on Negative Strand Viruses. June 2003, Pisa, Italy; Paper No. 215.

E.A. Fritz, L.E. Hensley, M. Martinez, K. Rubins, J. Huggins, P.B. Jahrling. Pathogenesis of Orthopoxvirus Infection. XVth International Poxvirus and Iridovirus Conference. September 2004, Oxford, England; Paper No. 83.

K. Rubins, L.E. Hensley, E.A. Fritz, J. Huggins, J. LeDuc, P.B. Jahrling, P. Brown. Comparative Analysis of Host and Viral Gene Expression During Smallpox, Monkeypox, and Vaccinia Infection Using Both in vitro and in vivo Primate Models. XVth International Poxvirus and Iridovirus Conference. September 2004, Oxford, England; W8.7.

E.A. Fritz, L.E. Hensley, C.L. Karp, R. Fisher, J. Paragas, H.A. Young, P.B. Jahrling, T.W. Geisbert. Evaluation of Interferon-beta as a Therapeutic Treatment for Ebola Hemorrhagic Fever in Nonhuman Primates. Cytokines in Cancer and Immunity. October 2004, San Juan, Puerto Rico; Paper No. 225.

Domestic

B. Yount, K.M. Curtis, E.A. Fritz, L.E. Hensley, P.B. Jahrling, E. Prentice, M.R. Denison, T.W. Geisbert, A.C. Sims, R.S. Baric. Reverse Genetics of a Full-Length Infectious cDNA of the Severe Acute Respiratory Disease Syndrome Coronavirus. 2004 Keystone Symposium on Bioterrorism and Emerging Infectious Diseases: Antimicrobials, Therapeutics and Immune-Modulators (K2). January 2004, Keystone, Co; Abstract No. 040.

L.E. Hensley, E.A. Fritz, C.L. Karp, R. Fisher, J. Paragas, H.A. Young, P.B. Jahrling. Evaluation of Interferon-beta as a Therapeutic Treatment for Ebola Hemorrhagic Fever in Nonhuman Primates. 2004 Keystone Symposium on Bioterrorism and Emerging Infectious Diseases: Antimicrobials, Therapeutics and Immune-Modulators (K2). January 2004, Keystone, Co; Abstract No. 207.

E.A. Fritz, D. Reed., H.A. Young, K.M. Daddario, K.H. Rubins, R.F. Fisher, T.W. Geisbert, L.E. Hensley. Role of Type I Interferons in the Pathogenesis of Filovirus Infection. XIII International Congress of Virology. July 2005, San Francisco, California; Poster No. 37.5-V-259.

T.W. Geisbert, S. Jones, E.A. Fritz, A.S. Shurtleff, J. B. Geisbert, R. Liebscher, A. Grolla, U. Stroher, L. Fernando, K.M. Daddario, M.S. Guttieri, B. Mothe, T. Larsen, L.E. Hensley, P.B. Jahrling, H. Feldmen. Live Attenuated Recombinant Vaccine Protects Nonhuman Primates Against a Lethal Challenge with Lassa Virus. XIII International Congress of Virology. July 2005, San Francisco, California; Session No. 126-V.

L.E. Hensley, T. Larsen, E.A. Fritz, J.B. Geisbert, K.M. Daddario, K.H. Rubins, D. Reed, R. Fisher, H.A. Young, T.W. Geisbert. Temporal Analysis of Marburg Hemorrhagic Fever in Cynomolgous Macaques. . XIII International Congress of Virology. July 2005, San Francisco, California; Session No. 89-V.

J.B. Geisbert, L.E. Hensley, K.M. Daddario, C. Nabel, E. Kagen, E.A. Fritz, P.B. Jahrling, G.J. Nabel, T.W. Geisbert, N.J. Sullivan. Inhibition of Ebola Virus Infection by Specific Viral Gene Silencing. . XIII International Congress of Virology. July 2005, San Francisco, California; Poster No. 48-V-155.

K. Rubins, L.E. Hensley, E.A. Fritz, R. Fisher, J. Huggins, J. LeDuc, P.B. Jahrling, P.Brown, D. Relman. Comparative Analysis of Host and Viral Gene Expression During Smallpox Infection Using in vitro and in vivo Primate Models. . XIII International Congress of Virology. July 2005, San Francisco, California; Poster No. 174-V-286.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

2005 NCI-Frederick-USAMRIID Summer Student Seminar Series. Frederick, Maryland; August 2005: Understanding Ebola and Marburg Virus Pathogenesis.

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

14) *POST-TENURE POSITION TITLE*

Guest Researcher

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

USAMRIID, Frederick, Maryland

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☒ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center <u>USAMRIID</u> | ☐ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

10 Development of knowledge, skills, and research productivity
Comments

LONG TERM VALUE

10 How the National Academies Associateship award affected your career to date
Comments

LAB SUPPORT

9 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments

ADVISER SUPPORT

10 Quality of mentoring from the Adviser

Comments

LPR SUPPORT

10 Quality administrative support from the LPR
Comments

NRC SUPPORT

10 Quality of administrative support from the NRC
Comments

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street NW
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator
website
www.national-academies.org/rap

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms
ID# 0275480

cc: Research Associateship Programs

Rev. 07/2006
cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine
National Research Council

PA

Fiscal


Rep

Research Associateship Programs

FINAL REPORT

Print Layout View

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Goff		First Name Arthur	M.I. J
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. Residence Street 5337 Duke Court City, State Zip Frederick, MD 21703		FORWARDING Phone(s) and E-Mail (if known) Home Phone: 301-695-6442 Alt. Phone: 301-788-9962 E-mail: Arthur.Goff@det.amedd.army.mil	
3) Today's Date November 28, 2006		Dates of Tenure from August 19, 2004 to October 31, 2006	
4) Agency AMRMC	Laboratory or Center USAMRIID	Division / Directorate / Department Virology	
5) Name of Laboratory NRC Adviser (and USMA Mentor, if applicable) Lisa Hensley, Ph.D.			
6) TITLE OF RESEARCH PROPOSAL Clinical management plan for Orthopox virus infection			

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) We have engineered a cowpox virus expressing the green fluorescent protein (eGFP) under control of the vaccinia virus (VV) early/late promoter.
- 2) Using the above mentioned recombinant virus we tested a novel class of drugs for anti-cowpox activity in mice.
- 3) Also using the mouse model of cowpox virus infection, we developed a model for vaccinia-induced myocarditis.
- 4) We also engineered a GFP-expressing Monkeypox virus (MPX-eGFP) that was used in conjunction with whole body fluorescence resonance imaging to develop a disease progression model for intravenous infection of Monkeypox in non-human primates.
- 5)
(USMA Davies Fellow: please add summary of teaching, including classes taught.)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

Currently there are no pathophysiological data regarding the clinical manifestations of orthopoxvirus infection in humans and furthermore no treatment plan. The research in progress will provide guidance for the treatment and care of orthopox virus infected humans. A novel wireless total implant telemetry system is used to monitor in real time the changes in several physiologic parameters in response to infection and treatment. These physiologic changes are correlated to serum cytokine levels and viral load. First, an initial observational study to follow simple clinical parameters in monkeys challenged by the intravenous route with monkeypox virus was done. Next a controlled treatment trial will employ a clinical management plan based on the World Health Organization's plan for the management of dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS) in humans.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

Goff, A.J. and Paragas, J. A Survey of Antiviral Drugs for Bioweapons. Accepted for publication in Antiviral Chemistry and Chemotherapy

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

Goff, A.J., Lawler, J., Twenhafel, N., Garrison, A., Hartmann, E., Shamblin, J., Mucker, E., Huggins, J.W., and Paragas, J. Orthopox-Induced Myocarditis. In Review at The American Journal of Pathology.

Goff, A.J., Hartmann, C., Garrison, A., Mucker, E., Huggins, J.W., and Paragas, J. Whole-Animal Visualization of Cowpox Virus Replication. Manuscript in preparation.

- 10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

- 11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Domestic

1) Goff, A.J., Hartmann, C., Garrison, A., Mucker, E., Huggins, J.W., and Paragas, J. Whole-Animal Visualization of Cowpox Virus Replication. Abstract #W37-1. The American Society for Virology 24th Annual Meeting. June 18th to June 22nd, 2005. Penn State University, University Park Campus, State College, Pennsylvania.

Using whole-body fluorescence reflective imaging (FRI), we were able to spatially and temporally monitor cowpox virus (CPV) replication in vivo. Smallpox and other orthopox viruses pose a significant bioterrorism and public health threat. There is a need to develop antiviral and vaccine strategies. For this reason, it is necessary to establish animal models that approximate the disease course of a human Variola virus infection. We have engineered a CPV expressing the green fluorescent protein (eGFP) under control of the vaccinia virus (VV) early/late promoter between the counterparts of VV Copenhagen genes J4R and J5L (CPV-eGFP). Adding eGFP to the CPV genome allowed for whole-body FRI of viral replication in vivo. Single-step growth curves of CPV and CPV-eGFP were comparable. The engineered virus had plaque morphology similar to that of the wild-type virus, in addition to expressing eGFP. In i.p.-infected mice, CPV-eGFP had an LD50 of 5.5Log10 as compared to 4.8Log10 for the wild-type virus ($X2(1)=5.05$, $p=0.0247$). Although there was a statistical difference in the LD50, there was no statistical difference for the mean time to death (CPV=7.0, CPV-eGFP=6.4, $X2(1)=1.39$, $p=0.2390$). Using whole-body FRI, CPV-eGFP was first detected in the mesenteric tissue above the small intestine on day 1 post-infection. On day 3, GFP signal was detected in all of the mesentery of the abdomen. The infection spread to the upper gastrointestinal tract and cells surrounding the liver on day 4. The virus infected all the organs in the lower abdomen by day 5 and had infected most major organs, except the heart and brain, by day 6. In addition, we were able to correlate viral load with disease progression, allowing for a more complete understanding of poxvirus infections.

2) Goff, A.J., Hartmann, C., Garrison, A., Mucker, E., Huggins, J.W., and Paragas, J. Whole-Animal Visualization of Cowpox Virus Replication. The International Congress of Virology. July 23rd to July 28th 2005. San Francisco, CA.

Background

Smallpox and other Orthopox viruses pose a significant bioterrorism and public health threat. There is a need to develop antiviral and vaccine strategies. For this reason, it is necessary to establish animal models that approximate the disease course of a human Variola virus infection.

Methods

We engineered a cowpox virus (CPV) expressing the green fluorescent protein (eGFP) under control of the vaccinia virus (VV) early/late promoter between the counterparts of VV Copenhagen genes J4R and J5L (CPV-eGFP). Adding eGFP to the CPV genome allowed for whole-body fluorescence reflective imaging (FRI) of viral replication in vivo.

Results

Single-step growth curves of CPV and CPV-eGFP were comparable. The engineered virus had plaque morphology similar to that of the wild-type virus, in addition to expressing eGFP. In i.p.-infected mice, CPV-eGFP had an LD50 of 5.5 log10 as compared to 4.8 log10 for the wild-type virus ($X2(1)=5.05$, $p=0.0247$). Although there was a statistical difference in the LD50, there was no statistical difference for the mean time to death (CPV=7.0, CPV-eGFP=6.4, $X2(1)=1.39$, $p=0.2390$). Using whole-body FRI, CPV-eGFP was first detected in the mesenteric tissue above the small intestine on day 1 postinfection. On day 3, GFP signal was detected in all of the mesentery of the abdomen. The infection spread to the upper gastrointestinal tract and cells surrounding the liver on day 4. The virus infected all the organs in the lower abdomen by day 5 and had infected most major organs, except the brain, by day 6. In addition, we were able to correlate viral load with disease progression, allowing for a more complete understanding of poxvirus infections.

Conclusions

Using FRI, we were able to spatially and temporally monitor CPV replication in vivo.

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

14) POST-TENURE POSITION TITLE

Research Scientist Level 4/Virologist

15) POST-TENURE ORGANIZATION Provide name and address of organization.

USAMRIID

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

☐ Remain at Host Agency as Permanent Employee

☒ Remain at Host Agency as Contract/Temporary Employee

- Abbreviate Host Laboratory/Center _____
- ☐ Research Position at Another US Government Laboratory
- ☐ Administrative Position at US Government Laboratory
- ☐ Research Position at Foreign Government Laboratory

- ☐ Research/Teaching at US College/University
- ☐ Research/Teaching at Foreign College/University
- ☐ Research/Administration in Industry
- ☐ Research/Administration in Non-Profit Organization
- ☐ Postdoctoral Research
- ☐ Self Employed
- ☐ Other: specify _____

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

- ☒ 8 Development of knowledge, skills, and research productivity
- Comments

LONG TERM VALUE

- ☒ 10 How the National Academies Associateship award affected your career to date
- Comments

LAB SUPPORT

- ☒ 10 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
- Comments

ADVISER/MENTOR SUPPORT

- ☒ 8 Quality of mentoring from the Lab NRC Adviser (USMA Mentor, if applicable)
- Comments

LPR SUPPORT

- ☒ 10 Quality administrative support from the LPR
- Comments

NRC SUPPORT

- ☒ 10 Quality of administrative support from the NRC
- Comments

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street NW
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator
website
www.national-academies.org/rap

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms
ID# 0496770

cc: Research Associateship Programs

Rev. 08/2006
cost-center #

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
Hoard-Fruchey		Heidi	M
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst.		Home Phone: 443-622-9000	
Street 605 Tupelo Ct		Alt. Phone: 443-622-6027	
City, State Zip Edgewood, MD 21040		E-mail: hoardheidi@hotmail.com	
3) Today's Date		Dates of Tenure	
April 24, 2006		from July 19, 2004 to April 28, 2006	
4) Agency	Laboratory or NASA Center	Division / Branch / Directorate	
AMRMC		Analytical Tox/Neurobehavioral Tox	

5) Name of Research Associateship Programs Adviser

Dr. Michael Adler

6) TITLE OF RESEARCH PROPOSAL

Characterization of botulinum toxin light chain stability and endoprotease activity

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Stability of BoNT/A and /B recombinant light chains (rLC) was assessed in 7 solutions with greatest stability in intracellular buffer followed by 40 mM HEPES pH 7.3. Both were more stable in water than expected with half-lives of >1 week.
- 2) BoNT/A rLC stability increases with increasing milkfat, but milkfat content did not affect BoNT/B rLC stability, suggesting lipids play a role in BoNT/A stability and factors contributing to stability may be serotype specific.
- 3) Compound 35 inhibits BoNT/A, /B, and /E LC activities, and is a potential broad range inhibitor of BoNT activity.
- 4) Two derivatives of compound 35 also inhibit BoNT/A and BoNT/B activity, suggesting that derivatives of compound 35 may be useful for treatment of BoNT intoxication.
- 5) In collaboration with CPT Angela Purcell, a capillary electrophoresis assay was developed for BoNT/A and /E activity.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

CPT Angela Purcell will continue using the developed CE assay to further characterize the activities of BoNTs. The stability studies have been completed. The compound 35 characterization will continue in the laboratory by other members.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

Heidi Hoard-Fruchey and Michael Adler. In vitro stability of botulinum neurotoxin serotypes A and B recombinant light chains in human serum, buffered solutions, water, and milk. Technical Report for the United States Army Medical Research Institute of Chemical Defense

Michael Adler, Andrew Ternay, James Nicholson, Brennie E. Hackley, Jr., and Heidi Hoard-Fruchey. Synthesis and evaluation of compound 35 as a potential botulinum neurotoxin inhibitor. Technical Report for the United States Army Medical Research Institute of Chemical Defense

Michael Adler, Heather Manley, Heidi Hoard-Fruchey. Suitability of clonal S26 cells for botulinum neurotoxin studies. Technical Report for the United States Army Medical Research Institute of Chemical Defense.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Hoard-Fruchey H, Smith L, Schmidt J, Adler M. (2005) #88: In vitro stability of botulinum neurotoxin serotypes A and B recombinant light chains in physiological solutions, water, and milk. The 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Denver, CO.

Domestic

Hoard-Fruchey H, Ternay AL, Smith L, Hackley BE, Adler M. (2005) P24: Inhibition of BoNT/A, /B, and /E light chains by compound 35 and derivatives. Interagency Botulism Research Coordinating Committee 42nd General Meeting, Baltimore, MD.

Gallagher SJ, Hoard-Fruchey H, Powers JC, Smith L, Hackley BE, Adler M. (2005) P23: Compound screen to identify botulinum neurotoxin serotype A and B inhibitors. Interagency Botulism Research Coordinating Committee 42nd General Meeting, Baltimore, MD.

Purcell A, Adler M, Smith L, Hoard-Fruchey H. (2005) P25: Capillary electrophoresis assays for botulinum neurotoxin studies. Interagency Botulism Research Coordinating Committee 42nd General Meeting, Baltimore, MD.

Hoard-Fruchey H, Smith L, Schmidt J, Adler M. (2004) E-7: A sensitive microplate assay for evaluating the botulinum neurotoxin A light chain. Interagency Botulism Research Coordinating Committee 41st General Meeting, College Park, MD.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

17 Nov 2004 Briefing for potential NRC candidates. Botulinum toxins: stability and therapeutics. USAMRICD, Aberdeen Proving Grounds, MD

28 Sept 2005 USAMRICD Expanded Staff Seminar. A capillary electrophoresis-based assay for botulinum neurotoxin catalytic activity. USAMRICD, Aberdeen Proving Grounds, MD

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

14) *POST-TENURE POSITION TITLE*

STAS contractor

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

USAMRICD
3100 Ricketts Point Rd
APG-EA, MD 21010

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- ☐ Remain at Host Agency as Permanent Employee
☒ Remain at Host Agency as Contract/Temporary Employee

Abbreviate Host Laboratory/Center USAMRICD

- ☐ Research Position at Another US Government Laboratory
☐ Administrative Position at US Government Laboratory
☐ Research Position at Foreign Government Laboratory

- ☐ Research/Teaching at US College/University
☐ Research/Teaching at Foreign College/University
☐ Research/Administration in Industry
☐ Research/Administration in Non-Profit Organization
☐ Postdoctoral Research
☐ Self Employed
☐ Other: specify _____

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

- ☒ Development of knowledge, skills, and research productivity

Comments

I think I could have been more productive if the amount of paperwork and mandatory training sessions (POSH, drug abuse/alcoholism, etc.) was reduced. I think I lost about a month to a month and a half every year to the training sessions alone.

LONG TERM VALUE

☒ 7 How the National Academies Associateship award affected your career to date

Comments

I felt isolated from the scientific community at large by the lack of seminars involving speakers from other institutes (especially academic institutes).

LAB SUPPORT

☒ 8 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.

Comments

Funding was not a problem. A proper orientation is needed for NRC associates at USAMRICD to introduce the government system of paperwork and training.

ADVISER SUPPORT

☐ Quality of mentoring from the Adviser

Comments

I decline evaluation of my adviser.

LPR SUPPORT

☒ 8 Quality administrative support from the LPR

Comments

USAMRICD needs to clarify procedure when Dr. Hackley is not available for approval and signatures.

NRC SUPPORT

☒ 10 Quality of administrative support from the NRC

Comments

My questions were always answered in a timely manner and making travel plans for conferences always went smoothly. You have a great staff!

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

US Postal Service mailing address

Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED

directly to your NRC coordinator
website
www.national-academies.org/rap

Express Delivery address

Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms

ID#

Research Associateship Programs

cc:


Rev. 08/2005

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

National Research Council



PA

Fiscal

Shop

Research Associateship Programs

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Johnson		First Name Erik	M.I. A
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. Street 1402 Dalmation Dr APT T3 City, State Zip 21017		FORWARDING Phone(s) and E-Mail (if known) Home Phone: 352-514-8564 Alt. Phone: 352-514-8562 E-mail: erik.a.johnson1@us.army.mil	
3) Today's Date January 16, 2007		Dates of Tenure from January 3, 2005 to January 3, 2007	
4) Agency AMRMC	Laboratory or Center	Division / Directorate / Department Analytical /Neuro Tox & Comp Med/ Path	
5) Name of Laboratory NRC Adviser (and USMA Mentor, if applicable) Gary Rockwood & Robert K Kan			

6) TITLE OF RESEARCH PROPOSAL

Investigation of the Biochemical Basis of Behavioral Deficits Seen after Exposure to Low Level Chemical Warfare Nerve Agents in Guinea Pigs

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Morris water maze (MWM) is not a good behavioral model for repeated, low dose soman or sarin exposure.
 - 2) Repeated, low dose exposures to soman do not lead to cytoskeletal or synaptic derangements nor does this exposure paradigm result in increased apoptosis in hippocampus or parietal cortex.
 - 3) Repeated, low dose exposures to soman does lead to significant changes in glutamate receptor immunoreactivity though the ramifications of this are not fully known.
 - 4) Characterized sixteen different antibodies for cross-species immunoreactivity in guinea pigs and wrote protocols to describe the process.
 - 5) Acute exposure to soman reveals no significant changes in synaptic or certain cytoskeletal protein immunoreactivities though significant changes were observed in neuron and astrocyte-specific proteins.
- (USMA Davies Fellow: please add summary of teaching, including classes taught.)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

My current research is focused on the role of inflammatory mediators in the observed brain pathology of acute soman exposure. We have found several key inflammatory cytokines and chemokines are upregulated early following soman exposure. Current data suggests that inflammation likely plays an integral role in the progression, severity and lethality of acute soman exposure even with antidote pretreatment.

9) PUBLICATIONS AND PAPERS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

none

b) Books, book chapters, other publications

Johnson EA, Daugherty KS, Gallagher SA, & DeFord SM. (2006) Analyzing protein changes in guinea pig tissue lysates using non-guinea pig specific antibodies: Procedures for Western blotting and examples using 16 individual antibodies for common CNS proteins. Technical report for USAMRICD, MAR 06, TR-06-xx.

c) Manuscripts in preparation, manuscripts submitted

Erik A. Johnson, Kelly S. Daugherty, Sarah J. Gallagher, Anita V. Moran and S. Michelle DeFord. (2007) Chronic glutamate receptor pathology following repeated sub-lethal soman exposure in the absence of Morris water maze deficits. Submitted to Journal of Neurobehavior JAN07

Erik A. Johnson, Denise Fath, Christina P. Tompkins and Robert K. Kan. (2007) Significant upregulation of inflammatory mediators in the brain following acute soman exposure. In Preparation.

Erik A. Johnson, Denise Fath, Christina P. Tompkins and Robert K. Kan. (2007) Inflammatory mediators are expressed by neural cells following acute soman exposure. In Preparation.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NRC ASSOCIATESHIP RESEARCH*

Provide titles, inventors, and dates of applications.

none

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

none

Domestic

E.A. Johnson, A. Moran, K.S. Daugherty, S.J. Gallagher & S.M. DeFord., REPEATED SUB-LETHAL EXPOSURE TO SOMAN PRODUCES SIGNIFICANT CHANGES IN GLUTAMATE RECEPTOR IMMUNOREACTIVITY IN THE ABSENCE OF SIGNIFICANT BEHAVIORAL CHANGES AS MEASURED BY THE MORRIS WATER MAZE. Society for Neuroscience National Meeting, 10/06, Atlanta, GA

E.A. Johnson, K.S. Daugherty, S.J. Gallagher and S.M. DeFord, REPEATED SUB-LETHAL EXPOSURE TO SOMAN PRODUCES SIGNIFICANT CHANGES IN GLUTAMATE RECEPTOR IMMUNOREACTIVITY IN THE ABSENCE OF SIGNIFICANT BEHAVIORAL CHANGES AS MEASURED BY THE MORRIS WATER MAZE. Bioscience Review 06/06, Hunt Valley, MD

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

12/06, Expression of inflammatory mediators following acute soman exposure. Aberdeen Proving Ground -Edgewood Area, MD

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

none

14) POST-TENURE POSITION TITLE

STAS contractor with Battelle

15) POST-TENURE ORGANIZATION Provide name and address of organization.

Same as before (USAMRICD)

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

- ☐ Remain at Host Agency as Permanent Employee
☒ Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center USAMRICD
☐ Research Position at Another US Government Laboratory
☐ Administrative Position at US Government Laboratory
☐ Research Position at Foreign Government Laboratory

- ☐ Research/Teaching at US College/University
☐ Research/Teaching at Foreign College/University
☐ Research/Administration in Industry
☐ Research/Administration in Non-Profit Organization
☐ Postdoctoral Research
☐ Self Employed
☐ Other: specify _____

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

10 Development of knowledge, skills, and research productivity
Comments

LONG TERM VALUE

7 How the NRC Associateship award affected your career to date
Comments

LAB SUPPORT

10 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments
All top notch. Funding was never an issue.

ADVISER/MENTOR SUPPORT

10 Quality of mentoring from the Lab NRC Adviser (USMA Mentor, if applicable)
Comments

Dr. Kan has been magnificent. He has really helped me grow as a scientist. Dr. Rockwood and I had very limited interaction. My work was outside the realm of his expertise.

LPR SUPPORT

5 Quality administrative support from the Agency/Lab NRC Program Representative (LPR)
Comments

I had very little interaction with Dr. Hackley, though he was helpful when I could find him. Dr. Kan is too new to properly evaluate but I think he will be much more hands on.

NRC SUPPORT

10 Quality of administrative support from the NRC
Comments

Always helpful

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

I think a better screening method for potential mentors would be very helpful. Though I had pretty good luck with my mentors, I know many of the other mentors around the institute were not suitable. Also, a more clearly defined status as NRC fellows is absolutely necessary for tax purposes. I know all the NRCs here I talked to raised red flags with the IRS every year that taxes was filed. Better guidance form the NRC is necessary with perhaps a form letter that can be sent to the IRS during filing or more clear instructions.

Mail & Delivery Address

NRC Research Associateship Programs
The National Academies
500 Fifth Street NW, 5th Fl. Rm. 568
Washington, DC 20001

**THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator**

<http://www7.national-academies.org/rap>

Suggestions for, or problems with, forms
should be directed to the forms manager,
Suzanne White, at swhite@nas.edu

ID# 0499190

Rev.10/2006

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Research Associateship Programs

FINAL REPORT

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Klas		First Name Sheri	M.I. D.
2) FORWARDING Address (for tax statement / final stipend check) 1909 Chambers Dr. Bozeman, MT 59715		FORWARDING Phone(s) and E-Mail (if known) Home phone: Alt. phone: E-mail: sheriklas@yahoo.com	
3) Today's Date February 23, 2006		Dates of Tenure from December 6, 2004 to February 28, 2006	
4) Agency AMRMC	Laboratory USAMRIID	or NASA Center	Division / Branch / Directorate

5) NAME OF RESEARCH ADVISER

Robert G. Ulrich

6) TITLE OF RESEARCH PROPOSAL

Generation and immunization of HLA*A201 restricted peptides from the pCD1 plasmid of Yersinia pestis to elicit specific Tc

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Identified 2 different HLA-A2 restricted CTL epitopes from Yersinia pestis
- 2) Discovered which human cell types can be infected by Yersinia pestis
- 3)
- 4)
- 5)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

During this first year we have successfully generated 3 peptides from the F1 protein of Yersinia pestis that were specific for the human HLAA-2 molecule. We picked the highest scoring peptides based on a mathematical algorithm (<http://www.syfpeithi.de/Scripts/MHCServer.dll/Info.htm>). These peptides were used in standard CTL assays to assess the ability of Y.pestis stimulated human T-cells to recognize the aforementioned peptides in a secondary response. The results from these experiments yielded 1 peptide (peptide A) that essentially every donor tested responded to favorably. Peptide B was responded to by approximately 60% of the donors, but the response was not as robust as peptide A. The final peptide was not responded to by any of the donors and therefore has become the negative control for the remainder of the studies.

9) PUBLICATIONS AND PAPERS RESULTING FROM THE NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

- a) Publications in peer-reviewed journals

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

Human immune cells have different susceptibilities to infection with *Yersinia pestis*.

Identification of HLA*A201 restricted CD8 epitopes from the F1 protein of *Yersinia pestis*.

10 *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM THE NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Domestic

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

14) *POST-TENURE POSITION TITLE*

Post-doctoral scientist

15) *POST-TENURE ORGANIZATION* Provide name and city of organization.

**Ligocyte Pharmaceuticals
Bozeman, MT**

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- ☐ Remain at Host Agency as Permanent Employee
- ☐ Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center _____
- ☐ Research Position at Another US Government Laboratory
- ☐ Administrative Position at US Government Laboratory
- ☐ Research Position at Foreign Government Laboratory

- ☐ Research/Teaching at US College/University
- ☐ Research/Teaching at Foreign College/University
- ☐ Research/Administration in Industry
- ☐ Research/Admin in Non-Profit Organization
- ☒ Postdoctoral Research
- ☐ Self Employed
- ☐ Other: specify _____

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor – excellent), please rate the following:

SHORT TERM VALUE

- 8.00 Development of knowledge, skills, and research productivity
Comments

LONG TERM VALUE

- 10 How the National Academies Associateship award affected your career to date
Comments

LAB SUPPORT

- 7 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments

ADVISER SUPPORT

- 10 Quality of mentoring from the Adviser
Comments

LPR SUPPORT

- 10 Quality administrative support from the LPR
Comments

NRC SUPPORT

- 10 Quality of administrative support from the NRC
Comments

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

US Postal Service mailing address

Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

n:\AO Forms

ID#

You may E-MAIL this form directly to your NRC Coordinator.

website

www.national-academies.org/rap

Research Associateship Programs

cc:

Express Delivery address

Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

Rev. 08/2005

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Fiscal

PA


Drap

Research Associateship Programs**FINAL REPORT**

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Kremenevskiy		First Name Igor	M.I.
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. c/o Alena Nareika Street 1714 N. Woodmere dr., Apt. 21 City, State Zip Charleston, SC, 29407		FORWARDING Phone(s) and E-mail (if known) Home Phone: +375-17-298-5087 Alt. Phone: 210-916-1972 E-mail: kremenevskiy@rambler.ru	
3) Today's Date August 15, 2006		Dates of Tenure from September 6, 2005 to September 1, 2006	
4) Agency AMRMC	Laboratory or Center USA ISR	Division / Branch / Directorate Hemostasis	



5) Name of Research Associateship Programs Adviser

Anthony E. Pusateri/ Michail A. Dubick

6) TITLE OF RESEARCH PROPOSAL

"Effect of Activated Recombinant Factor VII (rFVIIa) Administration on Survival in Swine during Hypovolemic Shock and Uncontrolled Hemorrhage"

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) We finished the model development phase. There were tested respiratory and metabolic acidosis models in pigs. It was confirmed some previously established procedures concerning anesthesia, catheters, and monitoring of hemodynamics.
- 2) Our experiments showed respiratory as well as metabolic acidosis induced the development of coagulopathy in the pigs. The restoration of pH did not restore blood coagulation.
- 3) Adding rFVIIa to pig plasma in vitro in dose 1.26µg/ml final plasma concentration increased the maximal thrombin generation, however it did not completely correct coagulopathy.
- 4) It was studied the effects different fluid solutions (Hextend and Lactated Ringer) on coagulation function of normal and hypothermic human plasma in vitro with and without 90µg/kg rFVIIa (1.26µg/ml final plasma concentration).
- 5) We modified the thrombin generation test (developed by Hemker H.C. et al. 1993; 2003). This assay is suitable for detecting treatment-depending changes in the kinetic of thrombin generation and monitoring the pharmacokinetics of rFVIIa.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

It was developed an experimental animal model of acidosis. The results of in vitro experiments provide further experimental evidence that rFVIIa may be useful in treating hemorrhage in trauma patients despite hemodilution from massive fluid resuscitation or presence of hypothermia and acidosis. The effects of rFVIIa will be tested on this acidosis model as well as hemorrhagic shock model in US Army ISR.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of Journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

NO

b) Books, book chapters, other publications

NO

c) Manuscripts in preparation, manuscripts submitted

NO

10) PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

NO

11) **PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES**

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

NO

Domestic

Kremenevskiy I, Pusateri AE, Scherer MR, Fedyk CG, Dubick MA, Delgado AV. Effect of hemodilution or hypothermia on thrombin generation in vitro: improvement with rFVIIa. Presented at the Advanced Technology Applications to Combat Casualty Care (ATACCC) Conference, St.Peterburg, Florida. 14-18 August 2006.

12) **SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES** Include dates, names and locations of seminars.

NO

13) **PROFESSIONAL AWARDS RECEIVED DURING TENURE**

NO

14) **POST-TENURE POSITION TITLE**

Postdoctoral Research Fellowship

15) **POST-TENURE ORGANIZATION** Provide name and address of organization.

Department of Experimental Pathology and Transfusiology
Republican Scientific-Practical Centre of Hematology and Transfusiology.
160 Dolginovskiy Tract, Minsk 220059, Belarus

16) **POST-TENURE POSITION STATUS / CATEGORY** Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☐ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center _____ | ☐ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☒ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) **APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM**

On a scale of 1 - 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

10 Development of knowledge, skills, and research productivity

Comments

NO

LONG TERM VALUE

10 How the National Academies Associateship award affected your career to date

Comments

I hope it will be in the future. I've gained experience.

LAB SUPPORT

8 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.

Comments

There was some problem to get regulary internet access.

ADVISER SUPPORT

10 Quality of mentoring from the Adviser

Comments

I satisfied quality of mentoring from my adviser Dr. Tony pusateri as well as Dr. Michael Dubick.

LPR SUPPORT

10 Quality administrative support from the LPR

Comments

NO

NRC SUPPORT

10 Quality of administrative support from the NRC

Comments

I greatly appreciate quality administrative support from the NRC. The staff is very qualified and ready to help in different situation.

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

NO

US Postal Service mailing address

Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED

directly to your NRC coordinator
website

www.national-academies.org/rap

Express Delivery address

Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:AO Form

ID# 0508020

Research Associateship Programs

cc:

Rev. 01/2006

cost-center #

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
Langston		Jeffrey	L
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst. Residence		Phone: 410-436-2723	
Street 2124 Fallston Road		Phone: 443-866-0310	
City, State Zip Fallston, MD 21047		E-mail: Jeffrey.Langston@us.army.mil	
3) Today's Date		Dates of Tenure	
May 12, 2006		from May 12, 2003 to May 11, 2006	
4) Agency	Laboratory or NASA Center	Division / Branch / Directorate	
AMRMC	USAMRICD	Analytical Toxicology/Neurobehavioral To	

5) Name of Research Associateship Programs Adviser

Gary A. Rockwood

6) TITLE OF RESEARCH PROPOSAL

Development of a Guinea Pig Test Battery to Assess the Behavioral Effects of Exposure to Chemical Warfare Nerve Agents

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Repeated exposure to CWNA at doses that produce behavioral effects often also induces overt toxicity. Doses of CWNA that produce overt toxicity may produce behavioral alterations that persist months after exposure.
- 2) Guinea pigs are suitable subjects for evaluating the behavioral effects of drugs and toxicants. Guinea pigs do not seem to perform well in tasks that require the animal to travel in open spaces (i.e., radial arm maze, open field).
- 3) Conducted dose-response study of GB with animals performing under progressive ratio schedule. Conducted dose-response study of VX with animals performing under progressive ratio schedule. Evaluated ability of animals to learn new task after VX.
- 4) Guinea pigs perform qualitatively similar to other rodent species on a variety of operant behavior tasks including: active avoidance, multiple schedules of reinforcement, simple schedules of reinforcement, delayed matching and discrimination.
- 5)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

N/A

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

Langston, J. L., Adkins, A. L., Moran, A. V., Rockwood, G. A., & Deford, M. S. (2005). Effects of sarin on the operant behavior of guinea pigs. *Neurotoxicol. Teratol.*, 27, 841-853.

b) Books, book chapters, other publications

N/A

c) Manuscripts in preparation, manuscripts submitted

Langston, J. L., Robinson, K. A., Moran, A. V., Rockwood, G. A., & Deford, M. S. (in preparation). Effects of VX on the operant behavior (Progressive Ratio, Extinction, and DRL acquisition) of guinea pigs.

Langston, J. L., Robinson, K. A., Moran, A. V., & Rockwood, G. A. (in preparation). Effects of VX on the DRL 30 sec schedule performance of guinea pigs.

Langston, J. L., Robinson, K. A., Moran, A. V., & Rockwood, G. A. (in preparation). Effects of VX on delayed-match-to-position performance of guinea pigs.

Langston, J. L. & Myers, T. M. (in preparation). Effects of VX on the acoustic startle respons of guinea pigs.

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*

Provide titles, inventors, and dates of applications.

n/a

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

n/a

Domestic

Langston, J. L., Robinson, K. A., Moran, A. V., Rockwood, G. A., & DeFord, S. M. (2006, June). Effects of subacute exposure to vx on operant behavior (progressive ratio and drl) in guinea pigs. Poster presented at the U.S. Army Medical Defense Bioscience Review 2006, Hunt Valley, MD.

Langston, J. L., Yourick, D., Kohli, A., Robison, C., Burr, L., & Lumley, L. A. (2006, June). Effects of acute exposure to soman (gd) on acoustic startle response and prepulse inhibition in rats. Poster presented at the U.S. Army Medical Defense Bioscience Review 2006, Hunt Valley, MD.

Langston, J. L., Crouch, M., Adkins, A., Moran, A. V., Rockwood, G. A., DeFord, S. M. (2004, May). Effects of sublethal repeated exposure to GB on operant behavior in guinea pigs. Poster presented at the U.S. Army Medical Defense Bioscience Review 2004, Hunt Valley, MD.

DeFord, S. M., Langston, J. L., Rockwood, G. A., Adkins, A., Kahler, D. W., Crouch, M., Roberson, G., Moran, A. V. (2004, May). Neuro-functional assessment following repeated sublethal CWNA exposure. Paper presented at the U. S. Army Medical Defense Bioscience Review 2004, Hunt Valley, MD.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

N/A

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

N/A

14) *POST-TENURE POSITION TITLE*

STAS subcontractor

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

USAMRICD

3100 Ricketts Point Road

Aberdeen Proving Ground, MD 21010

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

☐ Remain at Host Agency as Permanent Employee

☒ Remain at Host Agency as Contract/Temporary Employee

Abbreviate Host Laboratory/Center **USAMRICD**

☐ Research Position at Another US Government Laboratory

☐ Administrative Position at US Government Laboratory

☐ Research Position at Foreign Government Laboratory

☐ Research/Teaching at US College/University

☐ Research/Teaching at Foreign College/University

☐ Research/Administration in Industry

☐ Research/Administration in Non-Profit Organization

☐ Postdoctoral Research

☐ Self Employed

☐ Other: specify _____

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM* Please rate each of the following on a scale of 1 (poor) to 10 (excellent).

Your experience as a National Academies Research Associate in this federal Laboratory

7 Short-term value: development of knowledge, skills, and research productivity

Comments:

7 Long-term value: how the National Academies Associateship award affected your career to date

Comments:

Administrative Support

5 Quality of the support you received from the federal Laboratory

7 Quality of the support you received from the Research Associateship Programs staff (Leave blank, if not applicable – e.g., NIST)

Comments:

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

fax
202 – 334 – 2759

website
www.national-academies.org/rap
Research Associateship Programs

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

n:\AO Forms
ID#

cc:

Rev. 09/2003
cost-center #

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Miroshnikova		First Name Olga	M.I. V
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. Natalia Dyatkina Street 150 Pocceti Way City, State Zip Mountain View, CA 94040		FORWARDING Phone(s) and E-Mail (if known) Home Phone: 650-949-2790 Alt. Phone: 301-512-8565 E-mail: olga.mirosh@gmail.com	
3) Today's Date February 17, 2006		Dates of Tenure from February 24, 2003 to February 24, 2006	
4) Agency AMRMC	Laboratory or Center WRAIR	Division / Branch / Directorate Experimental Therapeutics	
5) Name of Research Associateship Programs Adviser Dr. Lin, A. J.			

6) TITLE OF RESEARCH PROPOSAL

Potential Inhibitors of Malaria Parasites.

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Designed and synthesized novel antimalarial drugs.
- 2) Conducted multiple-step synthesis of Michal acceptor-based peptidomimetic inhibitors.
- 3) Improved existing methods of peptide synthesis to optimize product yield and selectivity.
- 4) Developed new approaches to overcome Mitsunobu reaction separation problem of the final product from byproduct, dicarboalkoxy hydrazine (DCH).
- 5) Investigated Structure-Activity Relationship of compounds obtained.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

Finishing up the project and prepare manuscript for publication.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

N/A

b) Books, book chapters, other publications

N/A

c) Manuscripts in preparation, manuscripts submitted

Olga V. Miroshnikova, Shuren Zhu, Thomas H. Hudson, Lucia Gerena and Ai J. Lin. Design, synthesis and antimalarial activity of novel peptidomimetics based on Michael acceptor core.

10) PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

N/A

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

N/A

Domestic

Olga V. Miroshnikova, Shuren Zhu, Thomas H. Hudson, Lucia Gerena and Ai J. Lin. Design, synthesis and antimalarial activity of novel peptidomimetics based on Michael acceptor core. 229th ACS National meeting, San Diego, March 13-17, 2005.

Extending our design and synthesis of novel peptidomimetic antimalarials based on a Michael acceptor core, our efforts are directed toward lengthening of the peptide chain by addition of extra amino acids, such as phenylglycine, phenylalanine and homophenylalanine, into the Michael acceptor backbone. Peptide coupling of the Michael acceptor with amino acids resulted in a mixture of diastereomers, which were successfully separated by column chromatography. The purified isomers were coupled with a 5-substituted aminopyrimidinyl carboxyl acid to give the final products 1a-3a and 1b-3b in high yield. The products were evaluated for their in vitro antimalarial activities against *Plasmodium falciparum*.

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

N/A

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

N/A

14) POST-TENURE POSITION TITLE

Research Chemist

15) POST-TENURE ORGANIZATION Provide name and address of organization.

Walter Reed Army Inst. of Research
Department of Med. Chemistry
503 Robert Grant Ave
Silver Spring, MD 20910

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☒ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center WRAIR | ☐ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

☒ 10 Development of knowledge, skills, and research productivity
Comments

LONG TERM VALUE

☒ 10 How the National Academies Associateship award affected your career to date
Comments

LAB SUPPORT

☒ 10 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments

ADVISER SUPPORT

☒ 10 Quality of mentoring from the Adviser
Comments

LPR SUPPORT

☒ 10 Quality administrative support from the LPR
Comments

NRC SUPPORT

☒ 10 Quality of administrative support from the NRC
Comments

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

US Postal Service mailing address

Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

n:\AO Forms

ID#

THIS FORM SHOULD BE E-MAILED

directly to your NRC coordinator
website

www.national-academies.org/rap

Research Associateship Programs

cc:

Express Delivery address

Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

Rev. 01/2006

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Fiscal

PI

Scap


Research Associateship Programs

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Pearson		First Name Brooke	M.I.
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. Street 104 Park Ave #202 City, State Zip Gaithersburg, MD 20877		FORWARDING Phone(s) and E-Mail (if known) Home Phone: 240-506-7337 Alt. Phone: E-mail: bpearson23@gmail.com	
3) Today's Date September 26, 2006		Dates of Tenure from July 15, 2003 to October 1, 2006	
4) Agency AMRMC	Laboratory or Center USAMRIID	Division / Branch / Directorate Bacteriology Division	



5) Name of Research Associateship Programs Adviser

Dr. Arthur Friedlander

6) TITLE OF RESEARCH PROPOSAL

Characterization of the Antibody Response to Inhalational Anthrax in Humans

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) We determined the extent of the antibody response to the three components of the anthrax toxin: PA, LF and EF.
- 2) I have demonstrated that these antibodies are capable of blocking serum conversion of the full-length protective antigen (PA) to its active form.
- 3) These antibodies can also block the binding of full-length PA to the surface of cells.
- 4) I also demonstrated that the antibodies are able to block the cleavage of PA after it is already bound to cells.
- 5) Additionally, we demonstrated that antisera inhibits the enzymatic activity of the LF toxin.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

In order to further characterize the human immune response to anthrax, a collaboration with Diversa corporation has been established. This collaboration will allow me to identify the anthrax proteins which are immunogenic to humans. Toward this goal a method was developed for purifying anthrax bacilli membranes which were sent to Diversa to be analyzed using sera from human survivors of anthrax infection via PF2D technology. The identified proteins, which we refer to as the "immunome," represent the portion of the anthrax proteome which is immunogenic in humans. The individual immunoreactive proteins are currently being identified via mass spec. analysis

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

Pearson, B; Little, SF; Tobery, SA; Panchal, R; Friedlander, AM. "Functional Analysis of the Human Immune Response to the Toxins of Bacillus anthracis"

10) PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Pearson, B; Little, SF; Tobery, SA; Panchal, R; Friedlander, AM. "Functional Analysis of the Human Immune Response to Anthrax Lethal and Edema Toxins". Bacillus - ACT 2005 International Conference. Santa Fe, NM

Domestic

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

14) POST-TENURE POSITION TITLE

Senior Scientist

15) POST-TENURE ORGANIZATION Provide name and address of organization.

Cubic Applications, Inc.
5695 King Center Drive / Suite 300
Alexandria, VA 22315

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☐ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center _____ | ☒ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

- ☒ Development of knowledge, skills, and research productivity
Comments

LONG TERM VALUE

- ☒ How the National Academies Associateship award affected your career to date
Comments

LAB SUPPORT

- ☒ Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments

ADVISER SUPPORT

- ☒ Quality of mentoring from the Adviser
Comments

Dr. Friedlander is a very busy man and is often not at USAMRIID, This being said I think he worked hard to be available for me when I requested his help and guidance. However, if I didn't ask to see him, I often wouldn't see him for months at a time. In many ways it is nice to be trusted to work on your own. Personally I think I would have liked to have a more interactive mentorship.

LPR SUPPORT

- ☒ Quality administrative support from the LPR
Comments

I don't know what "LPR" stands for. If that means the lab I worked then I think the support I received administratively was excellent.

NRC SUPPORT

- ☒ Quality of administrative support from the NRC

Comments

I really had no contract with the NRC other than in the application and renewal process. Even then the forms were sent to me and I filled them out and then sent them back.

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

US Postal Service mailing address

Research Associateship Programs
The National Academies
500 Fifth Street NW
Washington, DC 20001

n:\AO Forms

ID# 0381400

THIS FORM SHOULD BE E-MAILED

directly to your NRC coordinator
website

www.national-academies.org/rap

cc:

Research Associateship Programs

Express Delivery address

Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

Rev. 07/2006

cost-center #

1* JKN Drap

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

Research Associateship Programs

FINAL REPORT

Print Layout View

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
Silvestri		Lynn	S
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst. Street 201 Plantation Club Dr #1510 City, State Zip Melbourne, FL 32940		Home Phone: Alt. Phone: 240-626-6090 E-mail: lynn.silvestri@hotmail.com	
3) Today's Date		Dates of Tenure	
January 10, 2006		from September 12, 2004 to January 31, 2006	
4) Agency	Laboratory or NASA Center	Division / Branch / Directorate	
AMRMC	USAMRIID	Bacteriology	

5) Name of Research Associateship Programs Adviser

Sina Bavari

6) TITLE OF RESEARCH PROPOSAL

Identification of Inhibitors of Filovirus RNA Polymerases

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Effective siRNA against components of the Ebola and Marburg polymerase complexes (L, VP35, VP30, and NP) were identified.
- 2) siRNAs were evaluated by Western blot after transfection of cells with siRNA and expression vectors. Transfection of cells with siRNA in various combinations followed by virus infection was effective in reducing virus titers.
- 3) Transfection of siRNA into mice by hydrodynamic shear did not protect mice from death from Ebola virus infection.
- 4) The amount of siRNA used, the delivery method, and lack of siRNA chemical modification for in vivo delivery likely contributed to themouse study results.
- 5)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

The identified siRNA sequences will be chemically modified to suit in vivo applications and re-tested in mice. Cellular targets for RNAi that may delay the function of the filovirus polymerase complex will be investigated.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

- a) Publications in peer-reviewed journals
- b) Books, book chapters, other publications
- c) Manuscripts in preparation, manuscripts submitted

10) PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH
Provide titles, inventors, and dates of applications.

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Domestic

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

14) *POST-TENURE POSITION TITLE*

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- | | |
|--|---|
| ☐ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☐ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center _____ | ☐ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☒ Other: specify <u>N/A</u> |

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

- ☒ 9 Development of knowledge, skills, and research productivity
Comments

LONG TERM VALUE

- ☒ 8 How the National Academies Associateship award affected your career to date
Comments

LAB SUPPORT

- ☒ 9 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.
Comments

ADVISER SUPPORT

- ☒ 10 Quality of mentoring from the Adviser
Comments

LPR SUPPORT

- ☒ 10 Quality administrative support from the LPR
Comments

NRC SUPPORT

- ☒ 10 Quality of administrative support from the NRC
Comments

18) *PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.*

US Postal Service mailing address
Research Associateship Programs
The National Academies
500 Fifth Street, NW [GR 322A]

THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator
website
www.national-academies.org/rap

Express Delivery address
Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]

Washington, DC 20001

n:AO Forms

ID#

Research Associateship Programs

cc:

Washington, DC 20007

Rev. 08/2005

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine
National Research Council

Fiscal PA BRAP
Research Associateship Programs

FINAL REPORT

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name		First Name	M.I.
TONDULI		LAURA	S
2) FORWARDING Address (to which your tax statement will be mailed)		FORWARDING Phone(s) and E-Mail (if known)	
Res. or Inst. Street 208 cours de le Libération City, State Zip 38100 Grenoble FRANCE		Home Phone: 240-505-4127 Alt. Phone: 301-319-3008 E-mail: laura.tonduli@na.amedd.army.mil	
3) Today's Date		Dates of Tenure	
November, 8 th , 2006		from February 17, 2004 to December 15, 2006	
4) Agency	Laboratory or Center	Division / Directorate / Department	
	WRAIR	Biochemistry	
5) Name of Laboratory NRC Adviser (and USMA Mentor, if applicable)			
Dr Bhupendra P Doctor			

6) TITLE OF RESEARCH PROPOSAL

EVALUATION OF VARIOUS REVERSIBLE ACETYLCHOLINESTERASE INHIBITORS AS POTENTIAL PRETREATMENTS AGAINST ORGANOPHOSPHATE INTOXICATION

7) SUMMARY OF RESEARCH DURING TENURE

Itemize significant findings in concise form, utilizing key concepts/words.

- 1) We build up a reliable and reproducible ex vivo method that mimics the in vivo situation of a subject pretreated with cholinesterase reversible inhibitors and then exposed to organophosphate agents (OPS).
- 2) With this method, we determined for 5 pretreatments (pyridostigmine, physostigmine, huperzine, tacrine and galanthamine) the kinetics of inhibition and recovery of cholinesterases activities after various OPs exposures (MEPQ or DEPQ or soman).
- 3) We compared these inhibitors between them to determine which one seem to be the more efficient when used a a pretreatment of a nerve agent intoxication.
- 4) We also determined the tissue distribution of exogenous human serum butyrylcholinesterase after intra muscular administration.
- 5) (USMA Davies Fellow: please add summary of teaching, including classes taught.)

8) RESEARCH IN PROGRESS

Describe in no more than 100 words.

We have investigated the efficacy of pyridostigmine, physostigmine, huperzine, tacrine and galanthamine as potential pretreatments against organophosphate intoxication (MEPQ, DEPQ or soman) using unprocessed guinea pig, rhesus monkey or human blood. Results showed that the time for recovery of AChE activity varied with the reversible inhibitor, the OP and the species used. With MEPQ, protected AChE activity completely recovered in most of the cases whereas with DEPQ, only part of it recovered. Recovery times were usually longer for AChE protected with tacrine and galanthamine compared with AChE protected with huperzine or pyridostigmine. Data obtained after soman exposure are still in progress.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH


Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

- Tonduli LS, Doctor BP, Saxena A. An ex vivo approach for the evaluation of reversible inhibitors as potential pretreatments against organophosphate toxicity 2005. Chem Biol Interact. 2005 Dec 15;157-158:426-7

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted



- Tonduli LS, Tipparaju P, Doctor BP, Saxena A. Screening of reversible cholinesterase inhibitors as potential pretreatments for organophosphate toxicity (manuscript in preparation)

- Sun W, Tonduli L, Doctor BP, Saxena A. Tissue distribution of human serum butyrylcholinesterase in guinea pigs (manuscript in preparation)

10) *PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH*
Provide titles, inventors, and dates of applications.

11) *PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES*

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

- Tonduli LS, Doctor BP, Saxena A. (Oct 2005) An ex vivo approach for the evaluation of reversible inhibitors as potential pretreatments against organophosphate toxicity. VIIIth International Meeting on Cholinesterases, Perugia, Italy.

Domestic

- Wei Sun, Laura Tonduli, B.P. Doctor, and Ashima Saxena. Tissue Distribution of Human Serum Butyrylcholinesterase in Guinea Pigs. Bioscience review, Hunt Valley, Maryland, May 2006.

- Tonduli LS, Tipparaju P, Doctor BP and Saxena A. The ex vivo evaluation of reversible cholinesterase inhibitors as potential pretreatments for organophosphate toxicity
Bioscience review, Hunt Valley, Maryland, May 2006.

12) *SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES* Include dates, names and locations of seminars.

- Tonduli LS, Doctor BP, Saxena A. (April, 20th, 2006). Evaluation of various acetylcholinesterase reversible inhibitors as potential pretreatments against organophosphate intoxication, WRAIR, Silver Spring, MD.

13) *PROFESSIONAL AWARDS RECEIVED DURING TENURE*

14) *POST-TENURE POSITION TITLE*

Unknown at that time

15) *POST-TENURE ORGANIZATION* Provide name and address of organization.

Unknown at that time

16) *POST-TENURE POSITION STATUS / CATEGORY* Please indicate only one.

- ☐ Remain at Host Agency as Permanent Employee
☐ Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center _____
☐ Research Position at Another US Government Laboratory
☐ Administrative Position at US Government Laboratory
☐ Research Position at Foreign Government Laboratory

- ☐ Research/Teaching at US College/University
☐ Research/Teaching at Foreign College/University
☐ Research/Administration in Industry
☐ Research/Administration in Non-Profit Organization
☒ Postdoctoral Research
☐ Self Employed
☐ Other: specify _____

17) *APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM*

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

8 Development of knowledge, skills, and research productivity

Comments

This fellowship allowed me to better understand the mechanisms involved in nerve agents intoxication and improved my expertise in the chemical warfare field.

LONG TERM VALUE

7 How the National Academies Associateship award affected your career to date

Comments

The NRC gave me the opportunity to work in a foreign laboratory and thus to have a different approach of the research in my field.

LAB SUPPORT

10 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.

Comments

All equipments and products I need to perform my work were available at all time.

ADVISER/MENTOR SUPPORT

9 Quality of mentoring from the Lab NRC Adviser (USMA Mentor, if applicable)

Comments

I had the chance to have two advisers, Dr Doctor and Dr Saxena who helped me make the most of my experience here. They both integrated me in the team very quickly and had always been very motivating and supportive.

LPR SUPPORT

8 Quality administrative support from the LPR

Comments

Dr Sara Rothman had been very precious in solving all the issues I had.

NRC SUPPORT

9 Quality of administrative support from the NRC

Comments

All NRC staff had been helpful and trustworthy in answering my questions.

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

Mail & Delivery Address

NRC Research Associateship Programs
The National Academies
500 Fifth Street NW, 5th Fl. Rm. 568
Washington, DC 20001

THIS FORM SHOULD BE E-MAILED
directly to your NRC coordinator

<http://www7.national-academies.org/rap>

Suggestions for, or problems with, forms
should be directed to the forms manager,
Suzanne White, at swhite@nas.edu

ID#

0380500

Rev.10/2006

cost-center #

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine
National Research Council

Fiscal


PA

Stop

Research Associateship Programs

FINAL REPORT

Print Layout View



Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Urso		First Name Maria	L
2) FORWARDING Address (to which your tax statement will be mailed) Res. or Inst. Street 6 Walden Drive, Unit 5 City, State Zip Natick, MA 01760		FORWARDING Phone(s) and E-Mail (if known) Home Phone: (413) 695-1697 Alt. Phone: N/A E-mail: maria.urso@us.army.mil	
3) Today's Date September 18, 2006		Dates of Tenure from July 10, 2006 to September 21, 2006	
4) Agency AMRMC	Laboratory or Center ARIEM	Division / Directorate / Department Military Performance Division	
5) Name of Laboratory NRC Adviser (and USMA Mentor, if applicable) Dr. Edward J. Zambraski			

6) TITLE OF RESEARCH PROPOSAL

Effects of Prior Injury on Skeletal Muscle Inflammatory Pathways in Response to Disuse and Reloading

7) SUMMARY OF RESEARCH DURING TENURE

Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Refined research proposal and learned additional laboratory techniques necessary to execute proposed experimental design.
- 2) Submitted a research proposal to the Scientific Review Committee to conduct a pilot experiment on pre-existing human samples. The purpose of this work is to explore the effects of muscle injury (due to resistance exercise) on protease activity.
- 3)
- 4)
- 5)

(USMA Davies Fellow: please add summary of teaching, including classes taught.)

8) RESEARCH IN PROGRESS

Describe in no more than 100 words.

Awaiting clearance from the Scientific Review Committee to conduct pilot experiment. Once pilot experiment is complete, I will begin work on the larger proposal.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

- a) Publications in peer-reviewed journals
N/A
- b) Books, book chapters, other publications
N/A
- c) Manuscripts in preparation, manuscripts submitted
N/A

10) PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

N/A

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Domestic

N/A

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

N/A

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

N/A

14) POST-TENURE POSITION TITLE

U.S. Army Officer. Rank-Captian, AOC- Biochemist

15) POST-TENURE ORGANIZATION Provide name and address of organization.

Department of the Army, 1 Reserve Way, St. Louis, MO 63132
Station: USARIEM, Kansas St., BLDG. 42, Natick, MA 01760

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

- | | |
|---|---|
| ☒ Remain at Host Agency as Permanent Employee | ☐ Research/Teaching at US College/University |
| ☐ Remain at Host Agency as Contract/Temporary Employee | ☐ Research/Teaching at Foreign College/University |
| Abbreviate Host Laboratory/Center <u>AMRMC</u> | ☐ Research/Administration in Industry |
| ☐ Research Position at Another US Government Laboratory | ☐ Research/Administration in Non-Profit Organization |
| ☐ Administrative Position at US Government Laboratory | ☐ Postdoctoral Research |
| ☐ Research Position at Foreign Government Laboratory | ☐ Self Employed |
| | ☐ Other: specify _____ |

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM

On a scale of 1 – 10 (poor - excellent), please rate the following:

SHORT TERM VALUE

10 Development of knowledge, skills, and research productivity

Comments

This award afforded me the unique opportunity to develop my own research ideas and protocols and work at my own pace.

LONG TERM VALUE

10 How the National Academies Associateship award affected your career to date

Comments

This award placed me in an environment where I was exposed to non-traditional career options. I am now going to serve my country as a research scientist for the US Army.

LAB SUPPORT

10 Quality of support--equipment, funding, orientation, safety and health guidelines, etc.

Comments

ADVISER/MENTOR SUPPORT

10 Quality of mentoring from the Lab NRC Adviser (USMA Mentor, if applicable)

Comments

Dr. Zambraski evaluated each of my ideas, discussed the scientific merit, and provided adequate guidance to insure that my research and learning experiences were optimal.

LPR SUPPORT

9 Quality administrative support from the LPR

Comments

NRC SUPPORT

10 Quality of administrative support from the NRC

Comments

The NRC was extremely helpful during my tenure, but most importantly, when I decided to change my career plans and become an officer in the US Army, the NRC team was extremely supportive and allowed for a seamless transition.

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

Research Associateship Programs
The National Academies
500 Fifth Street NW
Washington, DC 20001

n:\AO Forms

ID# 0621870

directly to your NRC coordinator
website

www.national-academies.org/rap

Research Associateship Programs

cc:

Research Associateship Programs
The National Academies
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

Rev. 08/2006

cost-center #